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description of activities of his/her own sector. This information could not be systematically verified by the authors 
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Foreword 
 
 
The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI) is a 
comprehensive framework for addressing issues related to innovation and access to essential health technologies 
for developing countries.  It aims to promote innovation, improve access, and build capacities in relevant areas 
and mobilize resources for these purposes. 
 
Comprising 8 elements, sub-elements and specific actions, the GSPA-PHI identifies a number of stakeholders 
against each specific action and specifies lead stakeholders within each group. The most important stakeholders 
are Member States. 
 
To facilitate the implementation of GSPA-PHI, WHO collaborates with many external stakeholders. Internally, 
work is shared across several departments in headquarters, as well as with regional and country offices. As part 
of the WHO implementation plan the Department of Public Health, Innovation and Intellectual Property seeks to 
capture and document national efforts and approaches to implementing the GSPA-PHI and to make information 
and lessons learned available to other stakeholders. 
 
WHO appreciates this publication by Switzerland which analyses the current and potential contribution of the 
Swiss institutions involved in the implementation of GSPA-PHI. Switzerland has been an active advocate and 
promoter of GSPA-PHI during its development. WHO looks forward to the next steps and acknowledges the 
endeavors of the Swiss Institutions behind this effort. 
 
 
Zafar Mirza 
Coordinator 
Department of Public Health, Innovation and Intellectual Property 
Innovation, Information, Evidence and Research 
World Health Organization 
Geneva  
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Preface 
The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI) 
adopted in May 2008 (WHA 61.21) takes up in a comprehensive way actions needed in the area of research and 
development (R&D), transfer of technology, intellectual property (IP), health system strengthening and financing. 
The strategy has not only succeeded in integrating the notion of IP as an incentive for R&D, but also in 
addressing those aspects where such incentives are not sufficient to cover the need for the development of new 
products to fight diseases which disproportionately affect developing countries and where the potential paying 
market is small or uncertain. Numerous Swiss actors are active since a long time in the topics covered by GSPA-
PHI. 
 
As a prime location of scientific research, Switzerland is home to a major pharmaceutical industry, internationally 
recognized public health and medical research institutions and non governmental organizations with a broad 
expertise in international health. Switzerland is committed to providing the best possible conditions for research, 
adequate protection of intellectual property and access to essential drugs for developing countries. The Swiss 
public sector is taking into account its responsibility to contribute to publicly finance research institutions, as well 
as to orient and organize research in order to address the needs of public health also globally. In spite of 
potentially conflicting policy goals there is a common will to act. Therefore the Swiss federal administration has 
established in 2005 an expert group on public health and intellectual property, where officials from all concerned 
federal entities work together towards a coherent position of Switzerland in all fora where these issues are dealt 
with. This group includes the Federal Office of Public Health, the Swiss Federal Institute of Intellectual Property, 
the Swiss Agency for Development and Cooperation, the Directorate of Political Affairs of the Foreign Ministry, the 
State Secretariat for Economic Affairs, the State Secretariat for Education and Research, the Swiss Agency for 
Therapeutic Products (Swissmedic). 
 
This inter-ministerial group of experts accompanied the negotiation process in WHO towards a Global Strategy 
and Plan of Action on Public Health, Innovation and Intellectual Property. The issue of the link between public 
health and intellectual property was first brought to international attention by a South African court case on the 
price of HIV drugs from 1997 to 2001. This was followed in 2001 by the Doha Ministerial Declaration on the 
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and Public Health. This Ministerial 
Declaration, while remaining fully committed to the TRIPS Agreement, called for an implementation of the 
Agreement that should respect the rights of the World Trade Organization (WTO) Member States regarding public 
health protection and access to medicines for all. 
 
Since then, Switzerland has been an active player in the various rounds of negotiations that led to the adoption of 
the GSPA-PHI. In 2003 the World Health Assembly Resolution WHA 56.27 mandated WHO to establish the WHO 
Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH), which was chaired by former 
Swiss President Mrs Ruth Dreifuss and financially supported by Switzerland. The CIPIH report showed the broad 
challenge and the complexity of the full innovation cycle: access to medicine needs basic research, applied 
research, drug development, production capacities, regulatory capacity and a health system able to deliver the 
right medicines at the right time to the right patients. This is linked to research policy and incentives, questions of 
intellectual property, commerce, pricing, regulation and strengthening of the health system. The CIPIH report was 
welcomed by resolution WHA59.24 drafted under a Swiss chair, which established the Intergovernmental Working 
Group on Public Health, Innovation and Intellectual Property (IGWG) with the mandate to negotiate a “soft law” 
instrument to implement recommendations of the CIPIH report. This IGWG negotiated from December 2006 to 
May 2008. The GSPA-PHI was adopted by the World Health Assemblies 2008 and 2009 in resolutions WHA 
61.24 and 62.16. As the GSPA-PHI states, advances in biomedical science have provided opportunities to 
develop new, affordable, safe and effective health products and medical devices, particularly those that meet 
public health needs, and urgent efforts must be made to make these advances more affordable, accessible and 
widely available in developing countries. 
 
We are convinced that negotiating international instruments is not a goal per se. Instruments such as the GSPA-
PHI are only useful if they are implemented and ultimately lead to concrete access of people to medicines. In view 
of the complexity of the subject and the fact that many actions are already under way, we have decided that our 
contribution in the initial phase of the implementation of the GSPA-PHI would be to establish a descriptive 
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overview of the actions taken so far by Swiss actors, both public and private. We have therefore jointly 
commissioned research on the contribution of five different sectors (the Swiss federal public administration, the 
academic sector, the NGOs, the private for profit sector and the public private partnerships) towards achieving the 
elements and objectives of the GSPA-PHI. The mandate was given to the Swiss Tropical and Public Health 
Institute (Swiss TPH) to provide an overview on how Switzerland is contributing to the GSPA-PHI. Aimed at 
improving synergies across and within sectors, the report reveals many interesting aspects of the implementation 
of the GSPA-PHI, and illustrates the comparative advantages and responsibilities of all the implicated Swiss 
private and public actors for the further commitment of Switzerland in the implementation of the GSPA-PHI. The 
Swiss TPH mandate has been supervised by the inter-ministerial expert group on public health and intellectual 
property.  
 
While this publication is primarily to show the Swiss involvement in GSPA-PHI, it is also part of a deliberate effort 
to improve coherence through the Swiss Health Foreign Policy, the first formal agreement between a ministry of 
health and a ministry of foreign affairs on a national global health policy adopted in 20061. The implementation of 
the GSPA-PHI is an excellent illustration of the challenges of and need for coherence in a global health policy of a 
country. Questions of domestic law, where Switzerland has implemented the possibility of compulsory licensing 
for the manufacturing and export of patented pharmaceutical products in its patent law, national research policy, 
technical cooperation with emerging economies, development cooperation to strengthen national health systems 
and Switzerland’s position in negotiations such as those in WHO, are closely interlinked. Each of these subjects 
falls under the responsibility of a different ministry. This requires a close and open minded collaboration between 
them. 
 
The Swiss contribution to the GSPA-PHI needs also to be put into the specific national context. First, the federal 
structure provides political autonomy to the cantons with consequent heterogeneity in terms of planning of 
services, including educational and scientific institutions, which are decentralized. Second, the Swiss political 
system is characterized by the consensus democracy and multiparty government with proportional representation 
and changing coalitions. Third, as a consequence of the subsidiary role of the Confederation, cantons are 
responsible for many services, including certain education policies. Fourth, as a result of this, Switzerland has a 
clear bottom-up approach on setting priorities for the allocation of government funding for research, where the 
scientifically most promising and best project will be funded. It is therefore difficult to impose a top-down 
approach, but it can make an important difference to make researchers aware of the challenge posed by the 
GSPA-PHI and invite them to address the research needs of developing countries through existing funding 
channels. Thus, many of the activities described in this report result from the public sector being an important 
partner in R&D, and from private initiatives (public private partnerships, private for profit or NGOs).  
 
Providing a comprehensive overview of the results achieved so far in implementing the GSPA-PHI by the various 
Swiss stakeholders has been a complex undertaking. It is however worth noting that, as a first consequence of 
this report on Swiss implementation of GSPA-PHI, awareness of the importance of further coordination among all 
the involved stakeholders has been raised. Effective information sharing has started and efforts to increase policy 
coherence have been initiated. We foresee further progress in this area and are confident that this report, from a 
Swiss perspective, will contribute to achieve the goals of the GSPA-PHI.  
 
 
 
Dr. Gaudenz Silberschmidt 
Vice-Director 
Federal Office of Public Health 
Bern 
 
                                                     
1 http://www.bag.admin.ch/themen/internationales/11103/11523/index.html?lang=en 
Maya Tissafi 
Vice-Director 
Swiss Agency for Development and Cooperation 
Bern 
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Swiss Health Foreign Policy: an instrument to enhance coordination and coherence 
 
An agreement on Swiss health foreign policy objectives was adopted by the Federal Department of Foreign Affairs and the 
Federal Department of Home Affairs (9 October 2006). The main goals of the Swiss health foreign policy have been (i) to 
protect the health interests of the Swiss population, (ii) to harmonise national and international health policies, (iii) to improve 
the effectiveness of international collaboration in the health areas, (iv) to improve the global health situation, and (v) to 
safeguard Switzerland's role as a host country to international organizations and a base for major companies working in the 
health sector. Should such interests contain certain conflicting elements, the health foreign policy is meant to reconcile 
divergences. The complex issues at stake in the GSPA-PHI call for coordination among the different governmental authorities 
in charge of public health, development cooperation, research promotion, intellectual property protection, economic questions 
and foreign policy in order to reach maximum coherence on two different levels: one where national priorities must be 
checked against international developments, and one where specific interests of public or private actors are balanced with 
those of other actors involved. The necessary level of coherence – not to be confused with complete alignment of position – 
is achieved through the coordinating efforts of the interdepartmental (inter-ministerial) expert group on public health and 
intellectual property. The mandate of this expert group, whose members represent all interested government bodies, is to 
contribute to the implementation of several medium-term goals and priorities defined by the Swiss health foreign policy. The 
following three (out of a total of 18) goals are particularly relevant in this context: 
 "Improve international access to essential drugs – both recognized and newly developed" (goal 9). 
 "Promote research to strengthen the empirical basis for effective health interventions. Influence the dialogue on global 
research priorities in the health field in order to reduce the disproportionate burden of disease in the southern 
hemisphere in a sustainable way" (goal 12).  
 "Ensure appropriate protection for intellectual property as an essential incentive for research into, and development of 
new drugs and vaccines" (goal 18). 
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Executive Summary 
After more than six years of negotiations, the WHO 
Global Strategy and Plan of Action on Public Health, 
Innovation and Intellectual Property (GSPA-PHI) 
was endorsed by the sixty-first World Health 
Assembly in May 2008. The GSPA-PHI promotes 
new thinking on innovation and access to 
medicines. It provides a framework with more than 
100 specific activities for needs-driven research, 
rather than purely market-driven research, focusing 
on target diseases that disproportionately affect 
people in developing countries. The framework is 
structured into eight key elements: (1) prioritising 
research and development needs, (2) promoting 
research and development, (3) building and 
improving innovative capacity, (4) transfer of 
technology, (5) application and management of 
intellectual property to contribute to innovation and 
to promote public health, (6) improving delivery and 
access, (7) promoting sustainable financing 
mechanisms, and (8) establishing monitoring and 
reporting systems. 
 
The Swiss government has been heavily engaged in 
the different phases of the negotiation process, and 
after the endorsement of the action plan, the focus 
lies now on its implementation.  
 
The aim of this assessment is to explore the 
contribution of Switzerland regarding the 
implementation of the GSPA-PHI, with the following 
specific objectives: 
 
 to identify the chief actors contributing to the 
strategy; 
 to describe the contribution and activities of five 
major sectors in relation to the WHO strategy; 
and 
 to describe existing approaches to 
implementing the WHO strategy. 
 
The contribution of Switzerland regarding the 
implementation of the GSPA-PHI was assessed in 
two steps. In a first step, an individual assessment 
of activities contributing to the implementation of the 
GSPA-PHI was done by five major actors, namely 
by the Federal Office of Public Health (FOPH) and 
the Swiss Federal Institute of Intellectual Property 
(IPI) for the Federal Offices, by the Swiss Academy 
of Medical Sciences (SAMS) for the academic 
sector, by Medicus Mundi Switzerland (MMS) for the 
non-governmental organisations (NGOs), by 
Interpharma for the private for-profit sector, and by 
the Swiss Tropical and Public Health Institute 
(Swiss TPH) for the public–private partnerships  
 
 
 
 
(PPPs). In a second step, the five individual 
assessments were consolidated into one report. 
This step required the addition of further information 
about activities contributing to the implementation of 
the action plan because of the partly incomplete 
individual reports. The additional information was 
mostly extracted from information available on the 
Internet but was also obtained through contacts with 
experts in the field.  
 
The current assessment shows that the Swiss 
sectors assessed in this report have proactively 
implemented all eight elements of the GSPA-PHI, 
although only the government has addressed all of 
them because element 8 involves only WHO and 
the government. It is noteworthy that there is a gap 
in the limited or dispersed interventions of the PPPs 
and the private for-profit sector in the domain of 
traditional medicine. 
 
Moreover, while the list of Swiss activities is quite 
comprehensive, it was beyond the scope of the 
assessment to determine the weight of the 
described activities, their resulting effects, or which 
activities should be sustained in the future.  
 
Furthermore, the assessment has a number of 
limitations, among others, the lack of a common 
methodology, shortcomings of the reporting tool, 
and to a certain extent, incompleteness in the 
reports submitted by different sectors. However, 
even taking the limitations into account, a voluntary 
coordination in terms of exchange of information 
and communication among different actors could 
enhance the synergies in respect to implementation 
of the GSPA-PHI.  
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1 Introduction 
After more than six years of negotiations, the Global 
Strategy and Plan of Action on Public Health, 
Innovation and Intellectual Property (GSPA-PHI) of 
the World Health Organization (WHO) was 
endorsed in May 2008 by the sixty-first World Health 
Assembly. The GSPA-PHI outlines more than 100 
specific actions across eight elements. The 
elements are described in more detail below in 
section 1.1. This global strategy and plan of action 
aims at providing a medium-term framework to 
secure an enhanced and sustainable basis for 
needs-driven, essential health research and 
development relevant to diseases that 
disproportionately affect developing countries, 
proposing clear objectives and priorities for research 
and development, and estimating funding needs in 
this area [1]. 
 
The Swiss government has been heavily engaged in 
the different phases of the negotiation process. 
Through the Swiss chairmanship of the Commission 
on Intellectual Property, Innovation and Public 
Health (CIPIH), Switzerland has provided crucial 
contributions to better understanding the 
determinants and challenges of innovation as an 
essential element for improving the health status of 
the most deprived populations. In the subsequent 
negotiating process of the WHO Intergovernmental 
Working Group on Public Health, Innovation and 
Intellectual Property (commonly referred to as 
IGWG), the Swiss government played the important 
role of facilitating an exchange of views and informal 
as well as formal discussions among WHO Member 
States, particularly involving industrialised countries 
and emerging economies and developing countries. 
The Swiss government has thus contributed to 
finding a delicate balance between the protection of 
intellectual property rights as an incentive for 
innovation and the necessity of making research 
results and new medical products accessible to low-
income countries. 
 
Now, as the negotiation process is over and the 
GSPA-PHI is endorsed, the focus lies on 
implementing the action plan. With the mapping of 
already existing activities that are contributing to 
implementation of the GSPA-PHI, the Swiss 
government would like to identify the contribution of 
Switzerland. 
 
1.1 The different elements of the GSPA-PHI 
Adopted by the World Health Assembly, the GSPA-
PHI promotes new thinking on innovation and 
access to medicines. It provides a framework for 
needs-driven research, rather than purely market- 
 
 
 
driven research, focusing on target diseases that 
disproportionately affect people in developing 
countries. It defines research and development 
(R&D) objectives and priorities and attempts to 
identify sustainable funding sources and 
mechanisms. 
 
The GSPA-PHI is grouped into eight key elements, 
which are further divided into sub-elements with 
specific activities (see Appendix 1). The eight key 
elements are as follows: 
 
(1) Prioritising research and development needs 
(3 sub-elements, 13 specific activities)  
Element 1 highlights that the health research and 
development policies of developed countries need 
to reflect adequately the health needs of developing 
countries. Gaps in research on Type II and Type III 
diseases and on the specific R&D needs of 
developing countries in relation to Type I diseases 
shall be identified2. Prioritising R&D according to 
public health needs in developing countries, 
including health-system strengthening activities, 
support of South–South partnerships and a focus on 
traditional medicine, are regarded as very important.  
 
(2) Promoting research and development (5 sub-
elements, 22 specific activities) 
This element encourages the promotion of national 
health research programs that take into 
consideration human resources and the 
implementation of research networks and initiatives 
at the national, regional, and international levels to 
increase research coordination. It stresses the need 
to increase developing countries' capacities to 
analyse and manage clinical trial data, to access 
publication and information related to research 
knowledge, results, and technology, and to publish 
peer-reviewed papers.  
 
(3) Building and improving innovative capacity 
(5 sub-elements, 18 specific activities) 
Element 3, which is related to capacity building, 
especially in developing countries, represents an 
essential component in the realisation of the GSPA-
PHI. Related investments in human resources (HR), 
knowledge sources, and regional centres of 
excellence shall be promoted. Associated policy 
support shall be provided to support effective 
policies for HR strengthening and development of 
innovative approaches toward safe, high-quality, 
                                                     
2 Type I diseases are incident in both rich and poor countries, with large 
numbers of vulnerable populations in each. Type II diseases are incident in 
both rich and poor countries, but with a substantial proportion of the cases in 
poor countries. Type III diseases are those that are overwhelmingly or 
exclusively incident in developing countries. The prevalence of diseases and 
thus their categorisation in the typology can evolve over time. 
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and good manufacturing practices for traditional 
medicine.  
 
(4) Transfer of technology  
(3 sub-elements, 9 specific activities)  
Element 4 highlights the need to support North–
South and South–South development cooperation, 
partnerships, and networks to build and improve 
transfer of technology related to health innovation. 
Of particular importance is technology that 
considers public health aspects. A feasibility 
analysis is envisaged to assess the advantages and 
disadvantages of innovative approaches such as 
voluntary patent pools.  
 
(5) Application and management of IP to 
contribute to innovation and to promote public 
health  
(3 sub-elements, 14 specific activities) 
Element 5 addresses relevant aspects of the current 
international regime on intellectual property that are 
related to the promotion of innovation capacity in 
developing countries and the protection of public 
health. Management and application of intellectual 
property rights with regard to public health, 
however, also include other aspects, such as how to 
negotiate license or material transfer agreements, 
how to read, analyse, and examine patent claims, 
and how to draft patenting strategies for research 
institutes or pharmaceutical companies. 
 
(6) Improving delivery and access (3 sub-
elements, 21 specific activities) 
Element 6 refers to improved delivery and access 
that shall be achieved through increased 
investments into the health delivery infrastructure 
and financing health products. The development of 
sustainable financing mechanisms as well as the 
promotion of human resources development are 
hereby emphasised. Furthermore, the quality, 
safety, and efficacy of health products and 
procedures shall be promoted through the following: 
strengthened national health authorities, developed 
country poverty reduction strategies, compliance 
with good manufacturing practices, compliance with 
ethical principles for clinical trials, and strengthened 
regional networks for clinical trial implementation. A 
competitive market environment shall also be 
created to improve availability and affordability of 
health products in line with public health policies 
and needs, e.g., through generic drug production, 
elimination of import tariffs, and monitoring of prices.  
 
(7) Promoting sustainable financing 
mechanisms  
(2 sub-elements and 6 specific activities) 
The importance of identifying, securing, and 
ensuring sustainable financing mechanisms for R&D 
represents a key element. A focus is placed on 
establishing an expert group for organisational 
purposes, setting up a database for financing 
sources, disbursing enough funds for further R&D, 
promoting best practices in public–private 
partnerships for research and product development, 
especially in developing countries, and monitoring 
their performance.  
 
(8) Establishing monitoring and reporting 
systems  
(2 sub-elements, 5 specific activities) 
A system shall be put in place to monitor 
performance and progress of the overall global 
strategy as well as of each element. A monitoring of 
investments in R&D in developing countries, of 
incentive mechanisms, and of the effect of 
intellectual property rights laws on development and 
access to medicine products shall also be ensured. 
A progress report will be submitted to the Health 
Assembly through the Executive Board every two 
years. A comprehensive evaluation of the strategy 
will be undertaken after four years.  
 
The WHO has taken on a guiding role and has the 
goal of supporting member states in developing and 
harmonising national R&D plans and coordinating 
joint efforts. Several stakeholders are or will be 
implementing the eight elements and 108 
corresponding activities3 defined in the GSPA-PHI. 
These stakeholders include: the WHO, WHO 
Member States, non-governmental organisations 
(NGOs), the pharmaceutical industry, academia, 
civil society organisations, the World Intellectual 
Property Organization (WIPO), the World Trade 
Organization (WTO), the United Nations Conference 
on Trade and Development (UNCTAD), and the 
United Nations Industrial Development Organization 
(UNIDO).  
1.2 The policy background for the 
implementation of the GSPA-PHI 
In any country, activities undertaken to implement 
the GSPA-PHI will take place in a given 
environment, more or less conducive to effective 
and efficient interventions aimed at improving 
needs-driven innovation and access to essential 
medical products for those in greatest need. 
Therefore, it is critical to consider the existing set of 
national policies because they are a key 
determinant of the implementation process. It is 
beyond the scope of the present exercise to explore 
all the existing policies and regulations affecting the 
complex elements of the GSPA-PHI. However, the 
following elements were taken into account: 
 
Switzerland is an industrialised democratic country 
with an important trade sector, a long tradition of 
diplomacy and development aid, and strong 
                                                     
3 See Appendix 1. 
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scientific and research institutions. These activities 
are supported and regulated by a wide array of 
policy and legal instruments in the respective 
domains of health, education, research and 
development, innovation and technology, and 
industry and trade, to name only a few of the most 
relevant sectors for the GSPA-PHI.  
 
The Swiss government has developed and adopted 
laws and policies at the federal level that frame 
many interventions of relevance for the GSPA-PHI, 
including: 
 
 The Federal Council’s Message on the 
Continuation of Technical Cooperation and 
Financial Aid for Developing Countries 2009–
2012 presents a unified strategy for the 
development cooperation of the Swiss 
government that aims, among other things, to 
help improve access of developing countries to 
basic resources in education, health, and 
hygiene and to develop knowledge and 
technologies in these countries [2]. 
 The “SDC Health Policy” of the Swiss Agency 
for Development and Cooperation (SDC) 
highlights the principles of equal partnerships 
with developing countries, policy and technical 
support based on these countries’ self-defined 
needs, and a comprehensive approach to 
health and its determinants [3].  
 The “Federal Law to Promote Research and 
Innovation (LPRI)”4 determines the principles of 
the promotion of scientific research and 
innovation and the support of the evaluation 
and application of research results, of the 
control of the coordination of research organs, 
and of the efficient use of federal funds for 
research and innovation [4]. 
 The recent amendment (July 2008) of the 
Patent Act makes provision for research 
exemption and compulsory licensing for the 
manufacturing and export of patented 
pharmaceutical products and thus facilitates 
access of the least developed countries to 
production capacities in Switzerland in order to 
procure medicines of utmost public health 
importance to them, to name only a few [5]. 
 
While the existence, relevance, and potential 
positive or negative interactions of Swiss policies in 
various sectors are not explored here, it is important 
to keep the Swiss legislative and regulatory 
background in mind when reading the report and for 
further qualifying the analysis. 
 
                                                     
4 Forschungs- und Innovationsförderungsgesetz (FIFG) / Loi fédérale sur 
l’encouragement de la recherche et de l’innovation (LERI) / Legge federale 
sulla promozione della ricerca e dell’innovazione (LPRI), SR 240.1 
2 Aims and Objectives 
The aim of this assessment is to explore the 
contribution of Switzerland regarding the 
implementation of the GSPA-PHI. 
 
The specific objectives are as follows: 
 
 to identify the chief actors contributing to the 
strategy; 
 to describe the contribution and activities of five 
major sectors in relation to the WHO strategy; 
and 
 to describe existing approaches to 
implementing the WHO strategy. 
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3 Methodology 
The approach to assessing the contribution of 
Switzerland regarding the implementation of the 
GSPA-PHI has been made in two steps. 
 
1. Step one included an individual assessment of 
activities contributing to the implementation of 
the GSPA-PHI done by five major sectors, 
namely the Federal Office of Public Health 
(FOPH) and the Swiss Federal Institute of 
Intellectual Property (IPI) for the Federal 
Offices, by the Swiss Academy of Medical 
Sciences (SAMS) for the academic sector, by 
Medicus Mundi Switzerland (MMS) for the 
NGOs, by Interpharma for the private for-profit 
sector, and by the Swiss Tropical and Public 
Health Institute (Swiss TPH) for the public–
private partnerships (PPPs).  
 
2. Step two included the consolidation of the five 
individual assessments into one final report. 
Because the information provided by the 
individual assessments was partly incomplete, 
further information on activities contributing to 
the implementation of the action plan was 
added during the process of consolidating the 
different contributions. The additional 
information was mostly extracted from 
information available on the Internet but was 
also obtained through contacts with experts in 
the field.  
 
The following experts were contacted:  
 
 Martine Berger, MD, specialised in international 
public health and policy advice on research for 
health, and involved in the development of the 
WHO Health Research Strategy and of the 
GSPA-PHI;  
 Professor Matthias Hamburger, Head of the 
Institute of Pharmaceutical Biology, University 
of Basel; 
 Slim Slama, MD, MPH, Programme Director of 
the Geneva Health Forum, Geneva University 
Hospitals; and 
 Laurent Miéville, Vice-President ASTP and 
Director of Unitec, Office of Technology 
Transfer, University of Geneva. 
 
The assessment describes current activities only. 
However, relevant past activities that are still 
actualised (e.g., the amendment of the Patent Act, 
SR 232.14) were also included. Another inclusion 
criterion is related to the actors having Swiss roots. 
For the private for-profit sector, only Roche and 
Novartis were included while other companies such 
as Pfizer, Merck, GlaxoSmithKline, etc., were 
excluded for not having Swiss roots. The same 
criterion was chosen for the selection of the PPPs. 
Some well-known international PPPs such as the 
Global Fund to Fight AIDS, Tuberculosis and 
Malaria (GFATM), UNITAID, and the Global Alliance 
for Vaccine and Immunization (GAVI), although 
registered and having their headquarters in 
Switzerland, were excluded for this assessment 
because the Swiss component concerns only 
location in Switzerland and their activities cannot be 
regarded as a Swiss contribution to the 
implementation of the WHO plan of action.  
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4 Contributions of the Different Sectors to 
the GSPA-PHI  
The following overview describes briefly the key 
activities of the Swiss Federal Offices, of the 
academic sector, of the NGOs, of the private for-
profit sector, and of the PPPs contributing to the 
implementation of the GSPA-PHI. The activities are 
outlined and framed according to these sectors; 
however, to a certain extent, overlaps are inherent 
to the activities of the strategy. Details of the 
contribution of each actor to the GSPA-PHI are 
given in Appendix 1. 
 
4.1 Swiss Federal Offices 
In Switzerland, the Federal Administration is 
composed of seven departments, the Federal 
Chancellery, and roughly 90 offices. Each 
department has a member of the Federal Council as 
its head and is divided into different units. 
 
Four out of the seven departments have at least one 
unit that runs different activities contributing to the 
implementation of the GSPA-PHI, as follows:  
 
 the Federal Department of Home Affairs 
comprises the Federal Office of Public Health 
and the State Secretariat for Education and 
Research;  
 the Federal Department of Foreign Affairs 
comprises the Swiss Agency for Development 
and Cooperation;  
 the Federal Department of Economic Affairs 
comprises the State Secretariat for Economic 
Affairs;  
 the Swiss Federal Institute of Intellectual 
Property has a service agreement with the 
Federal Department of Justice and Police; and  
 Swissmedic, the Swiss Agency for Therapeutic 
Products, has a service agreement with the 
Federal Department of Home Affairs [6].  
 
In the following subsection, the different 
contributions of each of these units are described 
more in detail. 
 
4.1.1 The State Secretariat for Education and 
Research (SER) 
SER is the federal government's specialised agency 
for drawing up and implementing policy in the area 
of science, research, university, and space policy in 
Switzerland. It coordinates related activities within 
the Federal Administration and ensures cooperation 
with the cantons [7].  
 
 
 
 
SER offers support to different programmes and 
institutes that run activities that fall within the scope 
of the WHO action plan, as follows: 
 
 supporting the Swiss TPH, which has a strong 
research focus on diseases that are prevalent in 
the South and in Eastern Europe and which is 
involved in capacity building within health 
systems of developing countries; 
 supporting two high-level research centres, the 
Centre Suisse de Recherches Scientifiques in 
Côte d’Ivoire and the Ifakara Health Institute in 
Tanzania; 
 supporting the Swiss Vaccine Research 
Institute in Lausanne, which is active in the 
search for a vaccine against HIV, through the 
international “Collaboration for AIDS Vaccine 
Discovery”; 
 supporting the Global Health Institute (GHI) of 
the Federal Institute of Technology Lausanne 
(EPFL), which is contributing to the 
understanding, diagnosis, prevention, and 
treatment of infectious diseases. The GHI 
comprises eight groups, all engaged in different 
facets of research linked to human health but 
with a strong emphasis on diseases of global 
importance such as HIV/AIDS, tuberculosis 
(TB), and malaria; 
 supporting the Swiss Network for International 
Studies (SNIS, which promotes academic 
research on phenomena that transcend 
traditional nation–state boundaries. The SNIS 
strongly encourages pluri-disciplinary research 
and fosters collaboration among Swiss 
organisations of higher education, international 
organisations, and NGOs.  
 taking part in the “European and Developing 
Countries Clinical Trials Partnership” (EDCTP), 
which aims to develop new clinical trials and to 
strengthen regional capacities to combat HIV 
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and AIDS, malaria, and TB in developing 
countries, in particular in sub-Saharan Africa; 
 participating in several COST research 
programmes (COST - European cooperation in 
the field of scientific and technical research); 
WHO is also a member of some COST 
research programmes; 
 participating in the 7th EU Framework 
Programme on Research and Development. 
This programme finances, among others, 
projects in the fields of cardiovascular diseases, 
diabetes, cancers, chronic respiratory diseases, 
and public health issues (e.g., tobacco use, 
physical inactivity, unhealthy diets, and the 
harmful use of alcohol) in Southern and Eastern 
countries and in international cooperation; and 
 signing bilateral research partnerships for 
fostering scientific collaboration with different 
priority countries, such as India and China. 
Some of these partnerships cover health topics 
as well. Because Swiss academic institutions 
coordinate these programs, these partnerships 
are described in more detail in section 4.2.8. 
 providing the funds for and mandating the 
Swiss national Science Foundation (SNSF) that 
established the NCCR programme North South 
 
The SER also commissioned the Web for 
Interdisciplinary Research and Expertise (WIRE) - a 
think tank of Bank Sarasin & Co Ltd and Collegium 
Helveticum of the Swiss Federal Institute of 
Technology Zurich (ETHZ) and the University of 
Zurich - to deliver a preliminary study of “open 
source in pharmaceutical research and the health 
service”.  
 
With these different activities, the SER is 
contributing to elements 1, 2, 3, 4, and 6 of the 
action plan.  
 
4.1.2 The Swiss Agency for Development and 
Cooperation (SDC) 
SDC is Switzerland’s international cooperation 
agency within the Federal Department of Foreign 
Affairs. In collaboration with other concerned federal 
offices, SDC is responsible for the overall 
coordination of development activities and 
cooperation with Southern countries and Eastern 
Europe, as well as for the humanitarian aid 
delivered by the Swiss Confederation [8].  
 
SDC supports health projects in bilateral 
cooperation with the following focus countries: 
Chad, Mozambique, Tanzania, Mali, Benin, Burundi, 
Rwanda, Democratic Republic of Congo (DRC), 
Bosnia-Herzegovina, Ukraine, Tajikistan, Moldova,  
 
 
and Kyrgyzstan. Most of the projects focus on 
strengthening health systems and health reform and 
are thus supporting governments in implementing 
the recommendations of the WHO plan of action.  
 
Furthermore, SDC is supporting governments in 
implementing the GSPA-PHI through financial and 
intellectual contributions and policy dialogue with 
the following multilateral organisations: United 
Nations Development Programme (UNDP), United 
Nations Population Fund (UNFPA), Joint United 
Nation Programme on HIV/AIDS (UNAIDS), the 
GFATM, United Nations’ Children Fund (UNICEF), 
WHO, the Special Programme for Research & 
Training in Tropical Diseases (TDR), the Special 
Programme on Human Reproductive Health 
Research (HRP), the African Development Bank, 
the World Bank, and the World Food Programme 
(WFP).  
 
Against that background, the SDC role as part of the 
Swiss contribution involves a focus on the following 
elements of the WHO plan of action: 
 
 contributing to the National Centre of 
Competence in Research (NCCR) North–South 
with health, planning, and sanitation as one 
research focus; 
 supporting various research institutions in some 
focus countries such as the Ifakara Health 
Research and Development Centre in 
Tanzania, which has the mission to develop and 
sustain district-based health research and 
development capable of generating new 
knowledge and relevant information for public 
health policy and action; 
 supporting national health programmes in 
countries such as Tanzania, Mozambique, 
Rwanda, Burundi, Bosnia-Herzegovina, and 
Kyrgyzstan; 
 supporting Primary Health Care Programmes 
(including social protection), e.g., in the East 
and Southern Africa region in Tanzania, 
Mozambique, Rwanda, DRC, Burundi, Chad, 
Mali, and Benin;  
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 partnering with and/or supporting different PPPs 
such as Medecins for Malaria Venture (MMV), 
Drugs for Neglected Diseases initiative (DNDi), 
NATNETS in Tanzania, and the Tanzanian 
Training Centre for International Health (TTCIH) 
in Ifakara; 
 piloting and capitalising on experiences with 
new aid modalities, fostering aid coordination 
among all stakeholders involved, with a sector-
wide approach in selected partner countries 
such as Tanzania, Mozambique, Rwanda, 
Burundi, and Kyrgyzstan and contribution to 
Health Sector Budget Support in Mozambique, 
Tanzania, and Kyrgyzstan; in addition, 
supporting the planning of human resource 
development, investment, and financing. 
 through facilitation, technical, and financial 
support, contributing to the prioritisation of 
health care in national agendas, especially in 
countries where health is a sector focus in the 
SDC cooperation strategy: Mozambique, 
Tanzania, Mali, Benin, Burundi, Rwanda, DRC, 
Bosnia-Herzegovina, Ukraine, Tajikistan, 
Moldova, and Kyrgyzstan; 
 providing support to the institutional building of 
traditional medicine associations to improve 
their efficiency, their lobbying ability, and their 
complementarities with the "modern" system 
(Tanzania, Mali); 
 providing a core contribution and board 
membership in TDR, a special programme co-
sponsored by UNICEF, UNDP, World Bank, 
and WHO that funds research in infectious 
tropical diseases and provides support and 
training to researchers and institutions in the 
countries where these diseases occur; TDR has 
developed its own strategy for implementing the 
parts of the GSPA-PHI most relevant to its 
expertise and focus; and  
 supporting the Council on Health Research for 
Development (COHRED) and the Global Forum 
on Health Research (GFHR). COHRED is 
specialised in supporting countries in areas 
such as health research system assessment 
and development, policy development, priority 
setting, and research 
communication/knowledge translation. In recent 
years, it has developed a new line of activity to 
support pharmaceutical innovation and access 
to essential medical products in Africa, in 
collaboration with New Partnership for Africa’s 
Development (NEPAD) and the WHO/Public 
Health and Innovation Secretariat, thus 
contributing to early implementation of the 
GSPA-PHI. The GFHR is committed to 
demonstrating the essential role of research 
and innovation for health and health equity, 
benefiting poor and marginalised populations. In 
November 2010, COHRED and the GFHR 
agreed to organisational integration.  
 
SDC is contributing to elements 1, 2, 3, 4, and 6 of 
the action plan.  
 
4.1.3 The State Secretariat for Economic 
Affairs (SECO) 
SECO is the federal government's centre of 
expertise for all core issues relating to economic 
policy. Its aim is to ensure sustainable economic 
growth by putting in place the necessary regulatory 
and economic policy conditions. In terms of foreign 
trade policy, SECO is active in formulating efficient, 
fair, and transparent rules for the world economy [9].  
 
SECO is working with specialists from the Institute 
of Intellectual Property as well as international and 
local experts on various bilateral projects aimed at 
improving and increasing the use of intellectual 
property (also in the area of public health and 
intellectual property) in developing countries as part 
of its economic development co-operation efforts. 
The overarching goal of the projects is to support 
developing countries in the development and 
implementation of an up-to-date system geared to 
their needs to protect intellectual property rights 
and, through that, to strengthen national 
development strategies, such as the fight against 
poverty and the encouragement of commerce, while 
upholding the provisions of the WTO/TRIPS 
agreement. SECO supports different projects in 
Vietnam, Laos, Azerbaijan, Ghana, Egypt, and 
Serbia.  
 
In Vietnam, for example, Switzerland was able to 
aid in the legal structuring of its new national 
legislation on intellectual property within the 
framework of the “Swiss Vietnamese Intellectual 
Property Project” and its predecessor project. The 
project included presenting various workshops on 
the topic of public health and intellectual property 
such as the protection of clinical test data and 
intellectual property legislation in the areas of 
biotechnology, pharmaceuticals, and agro 
technology.  
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WEIN (Economic Cooperation and Development 
Infrastructure Financing), SECO’s infrastructure 
support programme, is carrying out public health 
projects within the framework of mixed financing in 
Vietnam, Jordan, and Egypt. It involves technology 
transfer accompanied by technical assistance. In 
Jordan, projects are related to health care waste 
management in hospitals and ambulances for the 
international airports. In Egypt, projects target 
restructuring the blood transfusion system and 
upgrading radiology services in the hospitals of the 
Ministry of Health and Population.  
 
SECO is mainly contributing to elements 3 and 4 of 
the action plan. 
 
4.1.4 The Swiss Federal Office of Public 
Health (FOPH) 
As the national authority in health matters, the 
FOPH represents Switzerland in international 
organisations and in dealings with other countries. 
Within Switzerland, it is responsible—together with 
the cantons—for public health and the development 
of national health policy [10]. 
 
FOPH is also supporting activities on the 
international level that contribute to the 
implementation of the GSPA-PHI. 
 
For an initial period of two years, FOPH is financing 
the secondment of an intellectual property expert of  
 
 
the Federal Administration at the secretariat of 
WHO. This expert will advise and coordinate the 
implementation of the GSPA-PHI with regard to its 
intellectual property aspects. 
 
In 2005, the FOPH and the Federal Institute of 
Intellectual Property jointly created a core group of 
experts to coordinate the position of Switzerland on 
all issues concerning public health and intellectual 
property. This group brings together representatives 
of the ministries and offices responsible for health, 
intellectual property, development cooperation, 
research, economy and commerce, human rights, 
drug approval, and foreign affairs. 
 
At the Graduate Institute in Geneva, the FOPH 
supports the global health program organising 
courses on ‘health diplomacy’. Additionally, it has 
also foreseen integration of a course on ‘health and 
intellectual property’. 
 
In 2005, Switzerland and China concluded a 
Memorandum of Understanding (MoU) aimed at 
strengthening their relations and cooperation in the 
health sector. The MoU provides a framework for 
mutual exchanges on infectious diseases, health 
personnel, traditional Chinese medicine, and non-
communicable diseases. The intense cooperation 
led to two courses on global health diplomacy 
organised by the FOPH in China in 2009 and in 
2010, respectively. In addition, there will be 
partnerships between various Swiss cantons and 
Chinese cities on hospital planning. 
 
FOPH is competent to fix the maximal price at which 
a new drug (proved to be efficient, appropriate, and 
economical) can be reimbursed by the federal 
health insurance. Thus, it generally includes a 
financial incentive (premium for innovation) to 
promote innovation of new drugs (about 10–20% of 
the manufacturing price). 
 
The draft Federal Law relating to human research—
which will be submitted to the Swiss Parliament for 
adoption in autumn 20115—is based on ethical 
principles recognised at the international level. This 
national law will also regulate clinical trials in the 
future and assure that they are carried out in 
accordance with these ethical principles. 
 
With these different activities, the FOPH is 
contributing to elements 1, 3, 5, 6, and 8 of the 
action plan.  
                                                     
5 Expected to come into force on January 1, 2013. 
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4.1.5 The Swiss Federal Institute of 
Intellectual Property (IPI)  
The IPI is the federal agency for matters concerning 
intellectual property (IP) in Switzerland. It has a 
service agreement with the Federal Department of 
Justice and Police by which it is charged with the 
tasks of drafting legislation in the field of intellectual 
property, acting in an advisory capacity to the 
Federal Council and other federal administrators, 
and representing Switzerland at the international 
level [11].  
 
Switzerland implemented numerous 
recommendations from the CIPIH and the WHO 
global strategy and action plan when it put the 
amended Patent Act (SR 232.14) into force on July 
1, 2008. The act brings patent law up to date with 
the technological advancements and international 
developments of recent years. 
 
In the area of biotechnology inventions, a new 
amendment allows a license to be granted for using 
a patented invention as an instrument for further 
research. This provision assures that patents in this 
area cannot become obstacles to research; it 
guarantees freedom of research in the medical 
research area; and it eases access to research 
instruments as required by the Action Plan Element 
2.2. 
 
The amendment of the Patent Act also legislates on 
the so-called research exemption, which is 
recommended in action plan item 2.4 (e). The 
research exemption allows scientific research on an 
invention without the permission of the patent 
holder, under certain circumstances of 
demonstrated public health interest, thus 
streamlining research in the areas of biotechnology 
and pharmaceuticals. 
 
To prevent the misappropriation of genetic 
resources and traditional knowledge, the amended 
Patent Act now also obliges patent applicants to list 
details for the source of genetic resources and 
traditional knowledge. This measure creates greater 
transparency. It also simplifies later monitoring of 
the right to access the resources or, respectively, 
the knowledge, as well as the distribution of any 
economic benefits arising from the use of such and 
thus works towards implementing the 
recommendation in item 5.2 (e) of the action plan. 
 
The amendment also implements the action plan 
recommendation to introduce a so-called “Bolar”-
type provision (see Element 6.3 (a)). Producers of 
generic medicines are now allowed to undertake all 
required actions necessary for the approval of the 
medicine even during the lifespan of its patent. This 
includes experiments to gather data for drug 
approval as well as allowing the manufacturing, 
import, and storage of a patent-protected 
substance, insofar as the actions are for the 
purpose of acquiring approval of a pharmaceutical 
product. 
 
Switzerland was one of the first countries6 to 
implement the recommendation under Action Plan 
Element 5.2 (d), which requires WHO Member 
States to implement the August 30, 2003 decision of 
the WTO General Council, through its legislative 
amendment. This decision of the WTO allows WTO 
Member States with sufficient pharmaceutical 
manufacturing capacity to provide a compulsory 
license for the manufacturing and export of patented 
pharmaceutical products under clearly defined 
conditions. This measure should make it possible 
for developing countries with insufficient or no 
manufacturing capacity in the sector to have access 
to patented pharmaceutical products at prices they 
can afford, if they need them for responding to 
serious public health problems such as AIDS or 
malaria. 
 
As already described above for SECO, the Institute 
also carries out bilateral projects for SECO in 
developing countries to improve and increase the 
use of intellectual property rights, such as projects 
in Vietnam, Azerbaijan, and Serbia and Ghana, 
Laos, and Egypt.  
In the Vietnam project, the Institute helped to 
establish a database on traditional knowledge in 
which data on more than 2,000 traditional medicinal 
plants have been systematically collected and made 
accessible. Patent examiners regularly access 
these data to check novelty and inventive steps, 
particularly in the field of pharmaceutical inventions. 
This availability significantly facilitates substantive 
examination of patent applications. The database 
was one of the first of its kind in the world and was 
subsequently studied by other countries. The 
establishment of this database works towards 
implementing element 5.1 (f) of the action plan. 
 
The Institute also provides free patent searches to 
less developed countries so that these countries 
can inform themselves about the status of patents 
for medicinal products. In addition, the Institute 
regularly supports the WTO and WIPO in the 
presentation of seminars and training workshops on 
implementing the provisions of the WTO/TRIPS 
Agreement and the flexibility it has in the area of 
public health by sending experts. 
 
With these different activities, the IPI is contributing 
to elements 2, 5, and 6 of the action plan.  
                                                     
6 The amended patent law came into force on July 1, 2008. 
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4.1.6 Swissmedic 
Swissmedic is the central Swiss supervisory 
authority for therapeutic products. It is a public 
service organisation of the federal government and 
has a service agreement with the Department of 
Home Affairs. Its principle is to protect the health of 
humans and animals by ensuring that medicines 
and medical devices in Switzerland are effective 
and safe.  
 
Swissmedic has various co-operations with other 
regulatory and supervisory authorities and with 
international organisations in the sector of medicinal 
products and medical devices.  
 
For example, Swissmedic works closely with WHO 
by participating in expert commissions for the 
development of new guidelines or support for 
training projects.  
 
Swissmedic also participates regularly in the 
International Conference of Drug Regulatory 
Authorities (ICDRA) where it shares its expertise. 
Since 1980, the ICDRA has been providing drug 
regulatory authorities of WHO Member States with a 
forum to meet and discuss ways to strengthen 
collaboration. It continues to be an important tool for 
WHO and drug regulators in their efforts to 
harmonise regulation and improve the safety, 
efficacy, and quality of medicines globally. In 2008, 
this conference was organised, in close 
collaboration with WHO, in Switzerland [12, 13].  
 
Swissmedic is contributing to elements 3 and 6 of 
the action plan. 
4.1.7 Contributions of the Federal Offices to 
the different elements of the GSPA-PHI 
Summarising the contributions of the different 
Federal Offices, it can be stated that they are 
contributing as a whole to all different elements of 
the GSPA-PHI.  
 
A substantial part of the contribution is related to the 
allocation of funding. SER, for example, is mainly 
offering funding. It is mostly the academic sector, 
which then implements the different activities (see 
section 4.2. for more details). 
 
The contribution of SDC covers broader aspects 
and includes support for health projects in the 
bilateral cooperation with selected countries, 
support for the policy dialogue with different 
multilateral stakeholders, and the funding of 
selected programmes in the academic sector, such 
as, for example, the NCCR North–South 
programme.  
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SECO is carrying out public health projects in the 
field of infrastructure through the infrastructure 
support programme WEIN; in addition, it runs some 
of its activities in collaboration with the IPI. 
The contribution of FOPH covers a wide spectrum, 
including financial support, capacity building, 
sharing its expertise, and advocacy at the national 
and international levels. 
 
IPI is the actor involved in this assessment with the 
most relevant contribution to element 5 of the action 
plan, related to the application and management of 
intellectual property to contribute to innovation and 
promote public health.  
 
From the different sectors contributing to the 
implementation of this GSPA-PHI that are included 
in this assessment, the Federal Offices are the only 
sector contributing to element 8, related to the 
establishment of a monitoring and reporting system. 
This distinction can be explained by the fact that the 
key stakeholders for the activities under element 8 
are the governments and WHO.  
4.2 The Academic Sector 
The scientific cooperation of Switzerland with 
developing and emerging countries has a long 
tradition. More than 50 years ago, two research 
centres, the Centre Suisse de Recherches 
Scientifiques in Côte d’Ivoire and the Ifakara Health 
Institute in Tanzania, were established and 
subsequently integrated as partnering country 
institutions. Switzerland maintains ongoing close 
research and management activities with these 
centres. Besides these two research centres, 
research partnerships with institutions all over the 
world have been built up over the last decades and 
offer the basis for the implementation of many 
success stories for collaboration between 
Switzerland and partner countries. 
 
The following overview is structured into the main 
programmes that are supporting research in the 
academic sector in partnership with developing and 
emerging countries.  
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4.2.1 The NCCR North–South Programme 
This programme is one of the 28 NCCR7 
established so far by the Swiss National Science 
Foundation (SNSF). It is funded by the SNSF, the 
SDC, the home institution (University of Bern) and 
by self funding from project participants. 
 
The NCCR North–South encompasses a network of 
over 400 researchers active in more than 40 
countries worldwide. Its overall goal is to contribute  
to mitigating the negative effects of global change 
and enhancing sustainable development through 
partnership research, capacity development, and 
societal empowerment in developing and transition 
countries, while developing a formal institutional 
network among these countries and in Switzerland. 
The research activities are carried out in partnership 
with Swiss research organisations and partner 
institutions in Africa, Asia, and Latin America. 
 
The programme includes three thematic nodes, one 
of which is “Health, Services, Planning”. This node 
currently comprises four research projects, two of 
them in the field of health and the other two focused 
more on sanitation. The two health-related projects 
are 
 
 sexual and reproductive resilience of 
adolescents in East and West Africa and 
 social services and control of infectious 
diseases in mobile populations of Africa and 
Asia. 
 
The management centre is hosted by the Centre for 
Development and Environment of the Department of 
Geography at the University of Bern. It coordinates 
the research, reports, publications, and other 
programme activities. Coordinating partner 
institutions are the Swiss TPH in Basel and the 
Department of Water and Sanitation in Developing 
Countries in Dübendorf [14]. 
The NCCR North–South Programme itself 
contributes to elements 1, 2, and 3 of the GSPA-
PHI, and depending on the focus of the supported 
projects, it might also contribute to elements 4 and 6 
of the GSPA-PHI. 
 
4.2.2 Programme “Research partnerships 
with developing countries” (RPDC) 
This programme is supported jointly by the SNSF 
and the SDC and funds research partnership 
projects between Swiss universities and research 
institutions in the South [15]. The programme aims  
                                                     
7 National Centres of Competence in Research promote long-term research 
projects in areas of vital strategic importance for the development of science in 
Switzerland, for the economy of the country, and for Swiss society. They are 
mainly financed through federal funds, complemented by funds from the 
universities themselves and third-party funds. 
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at supporting high-quality research projects focusing 
on problems that are relevant for disadvantaged 
countries. It further encourages the development of 
North–South scientific interactions and partnerships. 
In this way, the programme contributes to capacity 
building and scientific performance in the South and 
helps these countries to integrate into the 
international scientific community.  
 
The programme is open to all disciplines. For the 
timeframe 2008 to 2012, 13 projects receive 
funding; five of these projects are in the field of 
health, all of them having a duration of three years 
[15]. 
 
The health related projects address the following 
topics: 
 
 TB epidemiology in Papua New Guinea and 
drug resistance monitoring using molecular 
markers (University of Basel) 
 Improving quality of health care for Tanzanian 
children: assessing the use of electronic 
decision support to promote evidence-based 
medicine and rational use of drugs (University 
of Basel) 
 Improving equity in access through adherence 
to HIV care and treatment (University of Basel) 
 Aetiology, prevention, and control of anemia in 
sub-Saharan Africa (ETHZ) 
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 Interactions of lead intoxication and iron 
deficiency in Morocco (ETHZ) 
 
Like the NCCR North–South Programme, the RPDC 
itself contributes to elements 1, 2, and 3 of the 
GSPA-PHI, and depending on the focus of the 
supported projects, it might also contribute to 
elements 4 and 6 of the GSPA-PHI. 
 
4.2.3 Research in Development and 
Cooperation of Swiss Universities for 
Applied Science 
The SDC supports the program of the Rectors’ 
Conference of the Swiss Universities of Applied 
Sciences for the promotion of research partnerships 
of Swiss Universities for Applied Science (UAS) and 
institutes in developing and transition countries. The 
program aims at realising application-oriented 
research and development, building research 
capacities, and transferring knowledge [16]. 
 
One example of such a project in the field of health 
is “Enabling Health Communication - Feasibility 
Study”, which is a research project of the Zurich 
University of Applied Sciences (ZHUAS) with the 
Kenya Medical Research Institute. The study aims 
to identify the most relevant subjects of future 
research in the area of health journalism and its link 
to behaviour change [16].  
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Contributions mainly concern elements 1, 2, and 3 
of the GSPA-PHI. 
4.2.4 Programme “Scientific Cooperation 
between Eastern Europe and 
Switzerland” (SCOPES)  
This programme is financed by the SNSF and SDC, 
and it promotes scientific cooperation between 
research groups and institutions in Switzerland, 
Eastern Europe, the Western Balkans, and Central 
Asia. The goal of SCOPES is the production and 
exchange of knowledge and the training of qualified 
scientists. In addition to the funding of research 
projects, SCOPES also supports institutional 
partnerships.  
 
The projects are open to all disciplines, and quite a 
few projects are related to fundamental research 
[17]. The following two examples are ongoing 
projects in the field of health: 
 
 Development of disability status assessment 
methodology for Georgia; University Hospital of 
Basel in collaboration with MED-CONSILIUM in 
Vevey and the Institute of Strategic Research in 
Tbilisi, Georgia 
 Clinical and Educational Telemedicine Network 
in Armenia: Telemedical cooperation between 
Armenia and Switzerland; University Hospital of 
Basel in collaboration with Pediatric Orthopedic 
Department of Health of Armenia - Arabkir Joint 
Medical Center and Institute of Child and 
Adolescent Health in Yerevan, Armenia, and 
Hardware and Software Development of 
"Orgservice" Computer Research Centre for 
PC, Yerevan, Armenia 
 
Contributions mainly concern elements 1, 2, and 3 
of the GSPA-PHI. 
 
4.2.5 Capacity development of SDC in the 
scientific sector 
SDC supports capacity development in the scientific 
sector through the University Exchange 
Programme, supporting exchanges between Swiss 
scientific institutions and developing countries for 
mutual, shared learning and the development of 
joint projects and through financing PhD and 
postdoctoral students who are conducting research 
at a Swiss institution in collaboration with a local 
partner institution [18, 19].  
 
Contributions mainly concern element 3 of the 
GSPA-PHI. 
 
 14 
4.2.6 Swiss Network for International Studies 
(SNIS) 
The SNIS promotes academic research on 
phenomena that transcend traditional nation–state 
boundaries. The SNIS strongly encourages pluri-
disciplinary research and fosters collaboration 
among Swiss organisations of higher education, 
international organisations, and NGOs. Bringing 
together academics, practitioners, and policy 
makers, the SNIS bridges the gap between theory 
and practice in international studies and contributes 
to sharpening the Swiss profile in this highly 
relevant field. The current projects do not focus 
primarily on health, but on health determinants, and 
include different sectors. 
 
The Governing Committee is composed of SNIS 
founding members from the University of Geneva 
and the Graduate Institute of International and 
Development Studies, Geneva, as well as 
institutional founding partners in Switzerland: the 
World Trade Institute, Bern; the Center for 
Comparative and International Studies, University of 
Zurich and the ETHZ; the Swiss TPH, Basel; and 
the Swiss Institute for International Economics and 
Applied Economic Research, University of St. 
Gallen. 
The SNIS is funded by the SER and the Department 
of Public Instruction of the Republic and Canton of 
Geneva [20].  
 
Contributions mainly concern elements 1, 2, and 3 
of the GSPA-PHI. 
 
4.2.7 Swiss Commission for Research 
Partnerships with Developing Countries 
(KFPE) 
The Swiss Academy of Sciences (SCNAT) supports 
and connects the natural sciences at the regional, 
national, and international levels. Because of its 
broad support of science, SCNAT is a 
representative and important partner in policy-
making within Switzerland. It relies on a network of 
over 35,000 scientists working within and at the 
interface of many different disciplines. SCNAT is 
devoted to making the future of scientific culture and 
research a priority and building a basis for dialogue 
between science and society. 
 
The SCNAT has established the Swiss Commission 
for Research Partnerships with Developing 
Countries (KFPE) [21]. KFPE is dedicated to 
promoting research partnerships with developing 
and transition countries. In this way, the commission 
seeks to contribute to sustainable and effective 
development and help find solutions to global 
problems. KFPE is engaged in Swiss scientific 
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policies and is committed to promoting the interests 
of researchers and their affiliated institutions on both 
national and international levels. It furthers 
innovative and development-oriented research and 
designs concepts for research strategies. In this 
context, KFPE ensures that partnership principles 
are followed, the quality of research is assured, and 
the interests of all partners are covered. 
 
Contributions mainly concern elements 1, 2, and 3 
of the GSPA-PHI. 
 
4.2.8 Bilateral research partnerships with 
priority countries 
As mentioned in section 4.1.1, SER has, in addition 
to the above programmes, signed bilateral research 
partnerships for fostering scientific collaboration with 
different priority countries, such as India, China, 
South Africa, Russia, South Korea, Brazil, Chile, 
and Japan. The agreements include joint research 
projects and faculty and student exchange 
programmes. Complementary funding is playing a 
key role in these research projects. For each 
agreement, there is a Swiss academic institution 
defined as being the coordinator and one as being 
the associated leading house [22]. For example, the 
collaboration with India is coordinated by the EPFL, 
with the University of Lausanne as the associated 
leading house [23], and the collaboration with South 
Africa is coordinated by the University of Basel, with 
the Swiss TPH as the associated leading house 
[24]. Of the 22 joint research projects with India, 12 
are in the field of human health sciences. The 16 
joint research projects with South Africa cover three 
main topics: Public Health & Biomedicine, Bio- & 
Nanotechnologies, and Human & Social Sciences. 
Of these, projects of the health sector include 
subjects such as: 
 
 Valorising the potential of South African 
medicinal plants—discovery of new natural 
products scaffolds as leads against neglected 
tropical diseases 
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 Analyses of geographical patterns of malaria 
transmission and mortality in Africa using 
Bayesian spatio-temporal modelling 
 South Africa/Swiss Initiative in HIV drug 
discovery from medicinal plants 
 
Contributions mainly concern elements 1, 2, and 3 
of the GSPA-PHI. 
 
4.2.9 Other projects of the academic sector 
In addition to projects funded by the 
abovementioned sources, a range of other projects 
are ongoing in the academic sector of Switzerland 
that are contributing to the implementation of the 
GSPA-PHI. The following overview lists some 
examples of such projects from universities, 
affiliated institutes of universities, and university 
hospitals. 
 
The Swiss TPH offers a long list of projects 
contributing to the implementation of the WHO 
action plan, as an academic institution and also as a 
partner in PPPs and product development 
partnerships (PDPs). While the PPPs with the Swiss 
TPH as partner are described in section 4.5., the 
following activities are examples related to projects 
where the institute is collaborating with other 
academic institutions and public partners [25]:  
 
 Being a member of the EANETT (Eastern 
African Network for Trypanosomiasis) 
 Being partner in the TDR business line 3 
network for compound screening and evaluation 
 Being partner in the EU-funded ARVMAC and 
AMASA projects, and in the Alliance for Clinical 
Research & Clinical Epidemiology (ARCEAU–
DRC)  
 Collaboration with the Egyptian Ministry of 
Health and Population in the Egypt–Swiss 
Radiology Project, funded by the Egyptian and 
Swiss governments 
 
The EPFL, in collaboration with the hospital of 
Lausanne, is supporting interesting projects in the 
areas of cancer and cardiovascular diseases as well 
as infectious diseases and immunology. In addition, 
the EPFL-SDC fund supports research projects 
conducted in partnership between a research unit at 
EPFL and a scientific institution of the South. This 
programme is open to all disciplines at the EPFL. Its 
primary objective is to promote scientific 
cooperation that offers solutions to important 
problems in developing and emerging countries and 
contributes to research capacity building in the 
partner countries [26]. Further contributions to the 
implementation of the GSPA-PHI are done through 
the GHI of the EPFL. The GHI comprises 8 groups, 
all engaged in different facets of research linked to 
human health but with strong emphasis on diseases 
of global importance such as HIV/AIDS, TB, and 
malaria [27]. 
 
The University of Lausanne also has research 
projects in the field of HIV and malaria, funded by 
the European Union (FP7 projects) and a project 
focusing on the development of a polio vaccine, in 
collaboration with WHO. Furthermore, in January 
2010 it has inaugurated a centre for ‘vaccine 
formulation and adjuvants’ to enhance appropriate 
adjuvants use in low and middle income countries 
and address the challenges of the WHO Global 
Adjuvant Development Initiative.8 Since October 
2010, the centre created the technology transfer 
hub aimed at developing a sustainable 
manufacturing of adjuvant for pandemic influenza 
[28]. 
 
The University of Zurich is currently building up 
partnerships with Makerere University in 
Uganda and the National University of Rwanda.  
 
The ZHUAS has a large network with partner 
universities all over the world, focusing on student 
exchanges, faculty exchanges, and cooperation in 
research projects. In the field of health professions, 
the University has settled a collaboration with the 
Health Science University Mongolia in Ulaanbaatar.  
 
The University of Geneva, in collaboration with the 
Foundation for Innovative New Diagnostics (FIND) 
and the Institute of Primate Research in Kenya, runs 
a project aimed at developing a simple method to 
confirm cure after treatment of sleeping sickness 
patients [29]. In addition, the University guarantees 
the recognition of diplomas delivered by the 
Graduate Institute in Geneva, which offers among 
other curricula a Global Health Programme [30].  
 
Many Swiss university hospitals have established 
partnerships with developing countries that may 
contribute, directly or indirectly, to the 
implementation of the GSPA-PHI. A recent survey, 
conducted between October 2007 and March 2009 
with all the Swiss hospitals and clinics, targeted 
identification of existing projects of international 
cooperation based on clear institutional strategies 
and supported accordingly with identifiable financial 
resources. Out of the 200 contacted institutions, 30 
reported having conducted cooperation 
interventions for a total of 93 projects.  
                                                     
8 1. Supply portfolio of proven adjuvants accessible to the 
public sector 2. Provide vaccine formulations services and 
training courses 3. Facilitate technology transfer of 
adjuvants to developing countries. 
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A more detailed analysis will be published soon in 
the Bulletin des Médecins Suisses. A few examples 
of projects contributing to the implementation of the 
GSPA-PHI include the University of Bamako training 
programme in pharmacy for the hospitals (with the 
involvement of the University Hospital of Geneva 
(HUG) and the University of Geneva), the RAFT 
project (le Réseau en Afrique Francophone pour la 
Télémédecine), coordinated by the HUG, in 
partnership with the Solidarity Fund of the Canton 
Geneva, Eagle Foundation, WHO, Université 
Numérique Francophone Mondiale, Health-on-the-
Net, and UNESCO and the joint project of the HUG 
with the B.P. Koirala Institute of Health Sciences of 
Dharan, Nepal, on visceral leishmaniasis, in 
collaboration with the Institute of Tropical Medicine 
in Antwerp, the London School of Tropical Medicine 
and Hygiene, and WHO. 
 
The HUG has established the “Commission of 
humanitarian affairs for supporting international 
development”, which enjoys its own financial fund. 
In January 2008, the Department of Community and 
First Intervention established the international and 
humanitarian medical service (SMIH, Service de 
Médecine Internationale et Humanitaire) aiming at 
training and innovation. SMIH’s field activities are 
implemented in close collaboration with the health 
authorities of the developing countries concerned 
and their local institutions and NGOs. 
 
The HUG, in partnership with the Faculty of 
Medicine of the University of Geneva and with the 
main international organisations in Geneva and 
around the world, has launched the Geneva Health 
Forum as a joint initiative. The “Geneva Forum: 
Towards Global Access to Health” is a biennial 
international conference organised by the SMIH that 
brings together on equal footing all the actors 
involved in the field of access to health. The Geneva 
Health Forum and the Global Access to Health 
Platform bring together the major stakeholders in 
global access to health, from field workers to policy-
makers. The Forum and the Platform together form 
a developing global network for international and 
inter-sectoral dialogue, aiming to facilitate the 
strengthening of health systems and basic health  
services and striving to keep global access to health 
on the international agenda [31].  
 
These research collaborations and joint research 
projects are mainly contributing to elements 1 and 2 
and also to element 3 of the GSPA-PHI. Some of 
the projects, such as the Geneva Health Forum, for 
example, contribute also to element 6 of the GSPA-
PHI.  
 
4.2.10 The contribution of the academic sector 
to the elements of the GSPA-PHI 
The academic sector contributes on different levels 
to the implementation of the GSPA-PHI. The main 
areas are related to the promotion and conduction 
of research (elements 1 and 2) and capacity 
building (element 3), which also belong to the 
general key missions of the academic sector. Swiss 
universities employ a number of foreign doctorate 
candidates and post-docs, some of them coming 
also from low-resource settings. This can be seen 
as an indirect but important contribution to capacity 
building in these countries. 
 
Specific institutes and programmes in the academic 
sector have been established for engaging in 
partnerships with developing countries and projects 
of international cooperation, such as the Global 
Health Programme at the Graduate Institute in 
Geneva, which is linked to the University of Geneva; 
the GHI, linked to the EPFL; and the Swiss TPH, as 
an affiliated institute of the University of Basel. 
These institutes and programmes clearly address 
the question of improving innovation and access.  
 
Different research partnerships are supported by 
federal offices and institutions. Together with the 
SDC, the SNSF promotes research partnerships 
with developing and transition countries through the 
RPDC and the SCOPES programme; in both 
programmes, health and biomedical research are 
thematically represented among many other topics. 
The partnerships are aimed at improving individual 
and institutional research capacities. Health issues 
are one of the main themes in the NCCR North–
South, co-financed by the SNSF and SDC. The 
SNIS, supported by the SER, promotes pluri-
disciplinary academic research on phenomena that 
transcend traditional nation–state boundaries. 
Research topics are related to health determinants. 
 
An important contribution of the academic sector is 
directed to element 2.4.a, related to the 
development of the Berlin Declaration. The 
declaration targets establishing open access to 
knowledge by using the Internet for distribution and 
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promoting greater access to the knowledge and 
technology relevant to meeting the public health 
needs of developing countries. This declaration has 
been signed by a number of Swiss academic 
institutions, such as the Swiss Foundation for 
Research in Social Sciences (FORS), the 
Universities of Fribourg, Bern, Basel, St. Gallen, and 
Zurich, the Paul Scherrer Institute, the Swiss 
Federal Institute of Zurich, the Rectors’ conference 
of the Swiss Universities of Applied Sciences, the 
Swiss National Science Foundation, the Swiss 
Academy of Medical Sciences, and the European 
Organization for Nuclear Research (CERN) [32]. 
With signing this declaration, the institutions declare 
their intent to offer open access to their original 
scientific research results, raw data and metadata, 
source materials, digital representations of pictorial 
and graphical materials, and scholarly multimedia 
material. 
 
The Swiss academic sector also contributes to the 
activities of element 4 of the GSPA-PHI, related to 
the transfer of knowledge and technology such as, 
for example, the Swiss–Egypt radiology project of 
the Swiss TPH and the technology transfer hub of 
the centre for ‘vaccine formulation and adjuvants’ of 
the University of Lausanne. Contributions to 
element 5 are made via many research and joint 
research projects following the Global Access 
Strategy, which is driven by the public health 
interest, ensuring the application of the most 
appropriate patent filing and licensing strategy in 
each case.  
 
The Geneva Health Forum provides an important 
contribution to element 6 of the GSPA-PHI, 
improving delivery and access, even while it is not 
the main focus of the academic sector. The Swiss 
TPH is involved in different access programmes, but 
they are mostly done in the context of PPPs and are 
therefore described in section 4.5. Finally, it can be 
argued that many of the small individual projects 
undertaken by Swiss hospitals and clinics, often as 
bilateral partnerships, in developing countries are 
geared towards improving health and health care 
systems, thus improving delivery and access. 
 
The SNSF in general and the universities and 
institutes being partner in different PDPs and PPPs 
contribute to the implementation of element 7 of the 
GSPA-PHI.  
4.3 Non-Governmental Organisations 
The assessment of Swiss NGO contributions to the 
implementation of the WHO GSPA-PHI was mainly 
based on the activities of the 43 NGOs represented 
in the Network Medicus Mundi Switzerland (MMS) 
working in the field of international health 
cooperation [33] as well as other developmental and 
humanitarian NGOs not formally part of the network. 
MMS coordinates the Swiss platform HIV/AIDS and 
international cooperation (aidsfocus.ch), bundling 
Swiss organisations engaged in the response to HIV 
and AIDS, which also were included. All NGOs 
working in international health cooperation and 
humanitarian aid contribute to capacity building and 
improving delivery and access to medicines and 
therapies oriented to the needs of the poor by 
supporting health programmes in cooperation with 
local hospitals, clinics, and community-based 
organisations. The current overview of activities 
contributing to the implementation of the GSPA-PHI 
focuses on research and development of neglected 
diseases, promotion of innovation capacity in 
traditional medicine, information sharing, capacity 
building, and challenges of intellectual property. It is 
only as comprehensive as possible and does not 
pretend to be complete.  
 
In general, Swiss NGOs are not well aware of the 
GSPA-PHI, even though they are confronted with 
the effect of lacking and overpriced medicines for 
neglected diseases and those diseases which 
disproportionately affect people in developing 
countries. Scattered activities and sensitisation 
efforts do exist to raise awareness about this topic 
area. MMS, for example, regularly publishes 
information updates about the WHO action plan on 
its website, in electronic news sources, and in the 
MMS-Bulletin. Directly or through the MMS platform, 
the Swiss NGOs are also well connected with 
international organisations that are specialised in 
this topic area such as Health Action International 
(HAI), MSF Access Campaign, Knowledge Ecology 
International (KEI), and the BUKO pharma 
campaign. A specific effort to highlight the effect of 
pharmaceutical research for countries of the South 
was taken up and discussed in the 2008 Berne 
Declaration (BD) pamphlet, “Pharmaceutical 
research and diseases of the South, a shameful 
negligence”.  
 
An overview of key projects/programmes of NGOs 
actively targeting the implementation of the WHO 
GSPA-PHI is presented in the following paragraphs. 
 
4.3.1 Médecins Sans Frontières (MSF) 
Switzerland 
MSF Switzerland is an international humanitarian 
organisation with headquarters based in Geneva. 
MSF is the most important and most active NGO in 
the field of R&D promotion and research policy, 
especially with regards to neglected diseases 
combining direct medical aid with the fight against 
the obstacles that prevent effective aid.  
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At the political level, MSF is frequently involved in 
dialogue with major decision-making actors at the 
governmental and international levels but at the 
same time very active at the grass-roots level by 
participating and organising petitions and 
demonstrations. MSF international is a founder 
member of DNDi, a PPP focusing on the promotion 
of R&D of affordable drugs for neglected and 
tropical diseases (see sector 4.5.). Founded in 
1981, MSF Switzerland represents one of five 
operational centres with projects focusing on TB in 
Kyrgyzstan and TB/AIDS co-infection in Swaziland 
[34]. MSF Switzerland defines its goal as saving 
lives and reducing suffering by providing medical 
care for individuals in crisis situations.  
 
Three GSPA-PHI areas of action where MSF 
Switzerland is currently involved are described 
below. 
 
Promoting research for neglected diseases 
MSF conducts critical assessments of drugs and 
diagnosis methods, which are currently under 
development for the neglected diseases visceral 
leishmaniasis, sleeping sickness, and Chagas 
disease. The aim is to encourage the research 
community from the North and the South to conduct 
and include field research in their studies and to 
define needs-oriented research and development 
priorities. At present, MSF Switzerland is managing 
a program targeting sleeping sickness (African 
trypanosomiasis) together with DNDi. It is testing a 
new therapy that is easier to use than conventional 
treatment and is already available in some 
countries.  
 
Access Campaign 
In 1999, MSF initiated the “Access Campaign”, 
which targets the dual problem associated with 
modern drug development: high-priced drugs on the 
one hand and a lack of research and development 
investments in diseases of developing countries on 
the other hand. The MSF approach consists of 
promoting medical innovation to develop and 
research for new drugs and vaccines, etc., and of 
increasing access to much-needed drugs at an 
affordable price. TB and HIV/AIDS are among the 
main diseases currently targeted.  
 
Patent pool campaign 
The implementation of the GSPA-PHI is heavily 
dependent on suitable and sustainable financing 
mechanisms. The WHO has established an expert 
group to identify potential innovative financing 
mechanisms to support R&D activities. Possible 
financing tools could be indirect taxes (taxes for 
specific products or transactions), voluntary 
contributions by the economic sector or consumers,  
or the establishment of new funds for health R&D. 
One specific idea that is supported by MSF is the 
establishment of a patent pool for effective drugs 
that are especially accessible for poor countries. 
The initiative of creating a voluntary patent pool for 
medicines was taken up in 2008 by UNITAID. MSF 
has launched a campaign in which it requests large 
pharmaceutical companies such as Abbot, 
Boehringer Ingelheim, Bristol-Myers, Squib, 
GlaxoSmithKline, Merck, and Pfizer to make their 
HIV drugs available in the patent pool. The patent 
pool focuses on increasing access to newer 
antiretroviral medicines through stimulating the 
production of generics and encouraging the 
development of adapted formulations such as fixed-
dose combinations of newer products and special 
formulations for children.  
 
The pool aims at voluntary collaboration of patent 
owners to share their patents and make their 
intellectual property available for generic production 
of antiretroviral drugs for marketing in low-resource 
settings [35].  
 
MSF mainly contributes to the GSPA-PHI elements 
1, 2, 5, 6, and 7, but also to element 3 through its 
daily work in countries, collaborating with local staff. 
 
4.3.2 Swiss Red Cross (SRC) 
The Swiss Red Cross (SRC) is a private 
humanitarian non-profit organisation. As a member 
of the worldwide network of the Red Cross, it carries 
out its work according to the principles of the 
International Red Cross and Red Crescent 
movement. In Switzerland, SRC is active in the 
 19 
social, health, migration, and education sectors and 
encourages voluntary work at the community level. 
Its international activities embrace emergency relief, 
reconstruction, and rehabilitation as well as 
development cooperation. While health is an 
important element in emergency relief and 
reconstruction (e.g., rehabilitation of health 
infrastructure after natural disasters), it is the main 
focus of intervention in the long-term development 
programmes.  
SRC is supporting health programmes in 26 
countries in Africa, Latin America, Asia, and Eastern 
Europe by strengthening community-based health 
systems through innovative approaches and 
methods (health promotion, disease prevention, 
creating access for the poor and marginalised 
population, strengthen public health structures, 
health financing, and capacity building and 
development of educational material) and 
community-based home care services. Community 
action for health and empowerment are key 
elements of the SRC approach. Through policy 
dialogue, technical assistance, technology transfer, 
and capacity building, SRC contributes to improving 
specific areas of health services (e.g., national 
blood transfusion or eye care services).  
 
Some examples of SRC activities are as follows:  
 
 Laos, Cambodia: Improving access to public 
health care through health equity funds for the 
poor, health insurance, quality improvement of 
services, and mobilisation of village 
communities for health promotion, water, and 
sanitation. 
 Ghana: Strengthening human resources, 
improving infrastructure and technology for eye 
care delivery, and introduction of monitoring 
systems for the quality of care.  
 Swaziland: Comprehensive HIV/AIDS 
programme (prevention, testing, counselling, 
treatment, home care) with a systemic and 
community approach.  
 Ecuador, Bolivia: Development of a culturally 
adapted model of a health system at the district 
level (in regions with mainly indigenous 
population) with strong involvement of civil 
society organisations. 
 Kyrgyzstan (SDC mandate): Support for the 
health reform process by improving the health 
infrastructure at the district and community 
levels; building up and strengthening of the 
health promotion system with community 
involvement (Community Action for Health). 
 Romania, Moldova, Belarus: Health promotion 
and strengthening the home-based care and 
Visiting Nurse services (capacity building, 
training of professionals, community 
participation). 
 Egypt (SECO mandate), Eritrea, Zimbabwe: 
Strengthening national blood transfusion 
services, improving quality management by 
technical assistance and technology transfer, 
enhancing certification of the blood transfusion 
services. 
 
SRC is mainly contributing to elements 3, 4, and 6 
of the GSPA-PHI. 
 
4.3.3 Novartis Foundation for Sustainable 
Development (NFSD) 
NFSD is a private non-profit–based 
organisation and represents one arm of the 
corporate responsibility portfolio of Novartis. 
Currently, NFSD is engaged in eight main projects 
and programs in sub-Saharan Africa and on the 
Indian subcontinent, all of them directly or indirectly 
related to health [36]. The following projects 
contribute to the realisation of the GSPA-PHI. 
 
Access programs  
NFSD currently runs different access programs. In 
Tanzania, one project focuses on improving access 
to malaria treatment, and the other project focuses 
on patient-centred TB care. In Mali, there is a 
program that targets improving access to primary 
health care services for rural populations, and in 
India, the project provides comprehensive leprosy 
care. Some of these access programs are set up as 
a PPP.  
 
Capacity-building projects 
NFSD runs three projects in the field of capacity 
building: one project is the ICATT project, offering a 
computer-based learning program for health 
professionals on the topic of Integrated 
Management of Childhood Illness (IMCI) in 
developing countries; the second project offers 
support to the Tanzanian Training Centre for 
International Health (TTCIH) in Ifakara, which is 
supported by the Tanzanian Ministry of Health and 
Social Welfare, the Swiss TPH and SDC. The third 
project is a telemedicine project in Ghana aimed at 
providing quality primary health services that are 
affordable and sustainable and that meet the needs 
of patients through appropriate mobile and 
information technologies. 
 
Novartis Foundation mainly contributes to GSPA-
PHI elements 3 and 6. 
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4.3.4 Afro-European Medical and Research 
Network (AEMRN) 
The Bern- and Liberia-based NGO, founded in 
2006, realises projects in various resource-poor 
countries, especially in sub-Saharan Africa. With a 
focus on health and educational projects, it has 
defined knowledge transfer as its key mission [37]. 
 
AEMRN acts as a platform where, among others, 
health specialists and nurses as well as those 
specialised in providing trainings can organise 
meetings, seminars, workshops, and conferences 
themselves. An example is the 2008 symposium on 
knowledge management, resource mobilisation, and 
HIV/AIDS research in low-income countries.  
Contributions mainly concern element 3 of the 
GSPA-PHI. 
 
4.3.5 Antenna Technologies (AT) 
Founded in 1989, AT is an NGO based in Geneva. 
Its members are primarily scientists, researchers, 
and engineers. Funding comes from foundations, 
private donations, and institutional funds. A major 
goal of the NGO is to improve the image of 
traditional medicine [38].  
 
AT is currently involved in traditional medicine–
related projects in Mauritania and Mali. The aim is to 
contribute to improved effectiveness, reduce risks, 
and strengthen the links between traditional and 
conventional knowledge. A concrete project 
example is the effort of Antenna researchers to 
identify herbal formulas for malaria treatment in an 
urban region in Mali. So far, six plant species have 
been identified that are being researched by the 
Swiss TPH in Basel in close cooperation with the 
Mali MoH. The project is supported by SDC. 
 
Contributions mainly concern element 1 of the 
GSPA-PHI. 
 
4.3.6 Esperanza Medicines Foundation 
The Swiss-based NGO Esperanza Medicines 
Foundation was founded in Basel in 2004 with the 
aim of making valuable contributions in non-profit 
research and development of safe, effective, and 
affordable HIV and AIDS drug therapies. These will 
be specifically designed to meet the unique needs 
and capabilities of developing countries [39].  
 
The current antiviral project aims at the discovery of 
potent and efficacious natural compounds with 
demonstrated anti–HIV-1 activity and is based 
on the screening of a well-characterised collection 
of natural products. Additionally, two projects deal 
with natural products that can potentially be used as 
topical microbicides for preventive use against HIV-
1 transmission through intercourse, such as 
Cyanovirin-N, a protein with clearly demonstrated 
activity as an inhibitor of viral transmission, and 
RANTES analogues that have been identified 
recently as effective inhibitors of vaginal HIV 
transmission in rhesus monkeys. 
Contributions mainly concern element 1 of the 
GSPA-PHI. 
 
4.3.7 mediCuba-Suisse 
Founded in 1992, the NGO supports a range of 
public health projects in Cuba. Regular information 
bulletins and annual reports as well as the 
homepage provide information about the various 
public health projects covering a range of topic 
areas such as promotion of R&D related to 
traditional medicine, HIV and AIDS prevention, 
cancer care, and continuous education measures 
for Cuban medical doctors in Switzerland [40].  
 
Traditional medicine 
In Cuba, mediCuba-Suisse is supporting the 
implementation of a regional centre for green and 
traditional medicine. The aim is to promote the 
innovation and application of basic R&D of 
traditional medicine. The program supports the 
collaboration of homeopathic reference pharmacies 
in five provinces with the goal of improving basic 
and continuous educational training programs, 
teaching, and research approaches and increasing 
the availability of homeopathic drugs and therapies.  
 
Financing raw materials for antibiotic production 
mediCuba-Suisse finances the purchase of raw 
materials for antibiotic production on an annual 
basis. The project allows Cuba to produce its own 
antibiotics, saving drug imports in the range of 10 
million Swiss Francs and covering 60% of Cuba’s 
annual antibiotic needs.  
 
Support of the national cancer clinic in Cuba 
The national cancer clinic based in Havana hosts 
the national cancer register. In 2006, the national 
department against cancer was founded for 
streamlining cancer prevention, diagnostics, and 
treatment at the central and local levels. All cancer-
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relevant data are managed by the cancer 
observatory and facilitate the identification of new 
control strategies. As a complement, a virtual 
network connects health centres and entities at the 
national, regional, and local levels with the national 
cancer institute and the statistical office. A new 
project focuses on cancer in children and on breast 
cancer. 
 
mediCuba-Suisse mainly contributes to GSPA-PHI 
elements 1, 3, 4, and 7.  
 
4.3.8 mission 21 
mission 21, the Protestant mission in Basel, is a 
community of churches and Christian organisations 
bringing together people of dissimilar countries and 
cultures, fostering contact with other ways of life, 
and providing tangible help wherever peace, justice, 
and the creation itself are under threat. mission 21 
works in 17 countries with 57 partner churches and 
organisations and assists in 100 projects, fighting 
against poverty, promoting health, resolving 
conflicts peacefully, and educating people in 
theology and the church [41]. By supporting and 
strengthening community-based health systems and 
clinics and the production and distribution of cost-
effective drugs from local plants and substances, 
access to health care services is promoted.  
 
mission 21 supports a project in Chile to increase 
access to affordable drugs based on herbal 
remedies. Training courses and workshops are 
offered on basic knowledge about health and 
diseases and how to produce simple remedies 
based on herbal essences. Close cooperation exists 
with the local Mapuche community and ensures the 
preservation of their traditional knowledge about 
herbal plants.  
 
mission 21 mainly contributes to GSPA-PHI 
elements 1 and 6. 
 
4.3.9 medico international schweiz 
medico international schweiz was founded in 1937 
as Centrale Sanitaire Suisse. It has a vision of 
assuring basic health care services for all. The NGO 
manages several health care–related projects in 
eight countries, with a focus on Central America, 
covering topic areas such as midwife training, HIV 
prevention, psychological support, and many more 
[42].  
SADEC, the local partner of medico international 
Switzerland in Chiapas, Mexico, works for 
community health and development and is active in 
the training of health promoters and midwives. A 
new focus of SADEC is herbal medicine. They 
started to work in this field with the aim of 
strengthening indigenous knowledge and autonomy. 
However, herbal medicine is not seen as a 
replacement but as an addition to conventional 
medicine.  
 
Another partner of medico international Switzerland 
is GPSIDA. This NGO works in Cuba in the field of 
HIV prevention.  
 
medico international schweiz mainly focuses on 
GSPA-PHI elements 3, 4, and 6. 
4.3.10 Berne Declaration (BD) 
BD is a Swiss NGO with more than 20,000 
members, founded in 1968, with the mission to 
promote equitable, sustainable, and democratic 
North–South relations. The most common activities 
comprise conducting research, organising public 
awareness campaigns, and carrying out advocacy 
work, e.g., on the following key topic areas: (1) 
international trade, (2) international financial 
relations, (3) corporate social accountability (Public 
Eye Awards), (4) agriculture, and (5) health [43].  
 
The BD campaigns for concrete improvements that 
benefit developing countries in their economic and 
political relations to Switzerland. 
 
The following BD initiatives are relevant for the 
GSPA-PHI: 
 
Misappropriation of traditional knowledge and rights 
of indigenous peoples 
The BD is uncovering and raising awareness of 
specific cases of biopiracy, some of which are 
related to health. Together with and in support of 
indigenous communities, the BD is filing appeals 
against abusive patenting by private companies of 
genetic resources resting on traditional knowledge, 
such as the pelargonium case from South Africa 
involving a German pharmaceutical company. 
Simultaneously, the BD is also actively involved in 
negotiations related to the patent law and to the 
Access and Benefit Sharing instruments of the 
Convention on Biological Diversity.  
 
Innovation and access to medicines 
As a member of HAI, the BD actively follows all the 
deliberations and developments related to these 
subjects at the WHO and in other international fora. 
The organisation has portrayed the situation in the 
field of pharmaceutical research in relation to 
developing countries in a 2008 publication entitled, 
“Pharmaceutical research and diseases of the 
South, a shameful negligence”, which was widely 
disseminated in Switzerland. Building on this 
accumulated expertise, the BD is advocating in 
Switzerland for the necessity of de-linking the cost 
of R&D from the prices of medicines and to define 
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needs-driven health research to improve innovation 
and access. 
 
Intellectual property and public health 
In the view of BD, a major and fundamental 
discrepancy exists between the desire of the 
general public to have access to affordable drugs 
and the goals of industry to generate profit through 
patenting. The GSPA-PHI suggests a compromise: 
countries of the South are supported in their efforts 
to build up suitable management systems for 
intellectual property that preserve their public health 
interests. In this regard, Swiss organisations are 
mainly active at the level of advocacy, especially BD 
and MSF. They closely monitor international 
negotiations and treaties and the practices of 
international private companies that might have a 
negative effect on access to drugs in developing 
countries. Some concrete examples for advocacy 
efforts by the BD are the campaigns against TRIPS-
plus bilateral free trade agreements with developing 
countries, the international mobilisation around the 
Novartis court cases in India, the critical analysis of 
IP-maximalist agendas to address the issues of 
compromised medicines or Pandemic Influenza 
Preparedness, and the open letter to the Swiss 
government regarding the issuance of compulsory 
licenses in Thailand (TRIPS flexibilities). 
 
Clinical trials in developing countries 
The number of clinical trials carried out in countries 
of the South by the pharmaceutical industry – either 
directly or through Contract Research Organisations 
(CRO) – has been increasing substantially over the 
last decade, raising much concern about ethical 
violations. The BD campaigned against the conduct 
of unethical studies. Subsequently, the BD is also 
actively involved in reflections at the European level 
related to the promotion of ethical principles for 
clinical trials and to more transparency. 
 
The GSPA-PHI contributions of BD mainly focus on 
elements 1, 2, 5, and 6. 
 
4.3.11 Swiss Aids Care International 
Established in 2003, the aim of the foundation is to 
help people with HIV and AIDS in the poorest 
countries in the world. It has set up ambulatory 
clinics that offer comprehensive medical treatment 
and care that take into account the local conditions 
and customs. The foundation is mainly funded 
through donations and SDC [44].  
 
Swiss Aids Care International finances the 
Newlands Clinic in Zimbabwe. Every year, 3,000 
HIV and AIDS patients receive treatment, and 100 
local doctors and nurses benefit from training 
opportunities in the field of clinical and 
comprehensive HIV care.  
 
The Swiss Aids Care International mainly 
contributes to GSPA-PHI elements 3, 4, and 6. 
 
4.3.12 SolidarMed 
SolidarMed, a Swiss NGO focusing on health in 
Africa, was founded in 1926. SolidarMed particularly 
focuses on primary health care in the most 
disadvantaged areas of Tanzania, Mozambique, 
Lesotho, Zambia, and Zimbabwe. It initiates health 
programmes to support the management of HIV and 
AIDS, cholera and malaria, hospital development, 
management support at district level, promotion of 
training opportunities for specialised staff, 
construction of health facilities, and support of 
health promotion and prevention initiatives [45]. 
A GSPA-PHI-relevant example is the program 
SMART (“SolidarMed Antiretroviral Treatment”) in 
Southern and Eastern Africa through which 
SolidarMed contributes to the strengthening of 
health systems to promote access to voluntary 
counselling and testing (VCT), treatment of sexually 
transmitted diseases, antiretroviral treatment for 
adults and children, and prevention of vertical HIV 
transmission for people in need. 
 
Another example is a project in Tanzania, where 
more than 10,000 nurses are needed to provide 
care for AIDS patients. SolidarMed has decided to 
invest in the provision of basic and continuous 
education opportunities and infrastructure support.  
The GSPA-PHI contributions mainly focus on 
elements 3, 4, and 6.  
4.3.13 NGO contribution to the elements of the 
GSPA-PHI 
Despite their differing knowledge about the details 
of the GSPA-PHI, Swiss NGO strategies 
contributing to the WHO Action Plan are manifold, 
which makes it difficult to classify them into 
universally valid categories. The most active players 
from the Swiss NGO sector are the BD, MSF, 
mediCuba-Suisse, the SRC, and the NFSD. 
 
As a whole, the NGOs are contributing to all 
elements except for element 8 of the GSPA-PHI, 
because element 8 involves only WHO and the 
government 
 
Although the promotion of research is not a central 
focus for many NGOs, it has to be highlighted that 
several Swiss NGOs attempt especially to combine 
conventional R&D with traditional medicine and try 
to support the use and distribution of traditional 
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medicine in coherence with international biodiversity 
conventions, with a view to assuring access to 
payable and needs-based medicines and 
compensation of the local population.  
 
Swiss NGOs appear in general to be strong in 
interlinking on-site programmes with political 
advocacy. Advocacy at the political level is 
commonly combined with activities to sensitise the 
general public. Some NGOs, such as MSF 
Switzerland and the BD, closely follow the 
international discussions and negotiations within the 
framework of the WHO, WTO, and private 
companies as well as the development of 
international treaties that influence on one side the 
prioritisation of research and on the other side 
access to medicines in developing countries.  
 
Swiss NGOs strongly emphasise capacity building 
(North–South, South–South) of local expertise 
through basic and continuous education. The large 
majority of Swiss NGOs support capacity-building 
measures in some way. Many of the NGOs offer 
services at the country level, involving local staff 
and therefore contributing to capacity building and 
skill transfer. Through their in-country projects, 
NGOs often also strengthen health surveillance and 
information systems. Nevertheless, they remain 
limited in terms of continuous analyses of their own 
concepts and use of recent research findings in their 
projects/programs.  
 
Swiss NGOs participate in programmes of applied 
research together with local and international 
partners. Compared to other players presented in 
other sections of this report, these programmes 
often target improved access to and distribution of 
medicines at an affordable price as well as the 
availability of affordable diagnoses and therapies for 
the poor. 
 
A key demand of several NGOs, such as MSF, but 
also KEI and HAI, is the development of new 
financing systems for R&D that are independent 
from market prices and production monopolies. The 
development of a patent pool, as initiated by 
UNITAID and strongly supported by MSF, is valued 
as a promising model by the NGO sector. 
4.4 The Private For-profit Sector 
The contribution of Switzerland to the 
implementation of the GSPA-PHI from the private 
for-profit sector focuses in the current assessment 
on the two big pharmaceutical companies Novartis 
and Roche, which have their roots in Switzerland 
and are therefore counted as Swiss companies, 
although they are big international companies. 
However, there are additional activities from smaller 
Swiss pharmaceutical and biotech companies 
contributing to the implementation of the action plan 
that are not taken into account in this assessment.  
4.4.1 Novartis 
Novartis’ mission is to discover, develop, and 
successfully market innovative products to prevent 
and cure diseases, to ease suffering, and to 
enhance quality of life. In addition, Novartis wants to 
provide a shareholder return that reflects 
outstanding performance and to adequately reward 
those who invest ideas and work in the company 
[46].  
 
Although Novartis has a strong focus on the 
markets in the industrialised countries, there are 
also some activities that contribute to the 
implementation of the GSPA-PHI. 
 
Activities in the field of drug research 
Regarding the contribution to drugs and vaccines for 
neglected diseases through drug discovery and 
vaccine research, Novartis has built up two 
corporate research institutions: the Novartis Institute 
for Tropical Diseases (NITD) in Singapore and the 
Novartis Vaccines Institute for Global Health 
(NVGH) in Siena. While NITD was set up as a PPP 
between Novartis and the Singapore Economic 
Development Board, NVGH is a not-for-profit 
research institute [47]. Activities of NITD 
contributing to the implementation of the GSPA-PHI 
in the context of this assessment report are 
described in the section 4.5.  
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NVGH was established by Novartis in 2007 and 
inaugurated in February 2008. It is dedicated to the 
translational research and development of vaccines. 
NVGH focuses on neglected diseases, especially 
diseases that are particularly devastating to 
developing countries. The fact that vaccines have 
saved billions of lives in the past century and are 
still the most cost-effective way of controlling the 
spread of infectious diseases is the reason why the 
target is vaccine research. The institute aims to 
bridge the translational gap between basic research 
and the subsequent technical product development 
and manufacturing. The gap is usually caused by 
the perceived risk of poor commercial return to be 
expected as the disease afflicts mainly developing 
countries. This perception limits investments in 
production and manufacturing. NVGH provides the 
means and expertise for pilot-scale vaccine 
production and human proof-of-concept studies. 
 
The institute works in partnership with universities, 
research institutes, and other public and private 
organisations to develop the scientific basis for 
vaccine development. It has a strong capacity-
building component. In addition, NVGH collaborates 
with organisations such as GAVI, WHO, UNICEF, 
and other nongovernmental and non-profit 
organisations to bring international attention to this 
important issue. 
 
Currently, NVGH is focusing its research on 
conjugate vaccines for diarrhoeal and enteric 
diseases, such as infections with Salmonella 
bacteria, which are important causes of infections 
and diseases in children [48]. 
 
Novartis is an active partner of WHO and other 
stakeholders on R&D financing for neglected 
diseases and has developed a proposal for a Fund 
for Research and Development in Neglected 
Diseases (FRIND).  
 
Activities to increase access to medicines 
Novartis is one of the world's largest generic 
producers and is also running several “access to 
medicines” projects in low-resource settings. The 
approach to access is patient-centric and meant to 
enable superior patient outcomes. The access 
programmes are tailored to patient needs: from 
prevention to treatment and from donations to 
shared contribution or co-pay models [49]. In this 
respect, according to the company, 387,000 
patients with fascioliasis received free Egaten® 
treatment in 2009; 5 million of the 14 million people 
that have been cured of leprosy since 1985 were 
treated with drugs provided free of charge by 
Novartis since 2000. Vaccines and medicines 
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developed through the NITD and NVGH research 
programs will be made available at not-for-profit 
prices.  
 
In partnership with the WHO, UNICEF, and the 
Presidents Malaria Initiative (PMI), Novartis 
provides the antimalarial medicine Coartem® on a 
non-profit basis for public-sector use in developing 
countries in Africa, Asia, and Latin America. During 
2009, 75 million patients received treatment courses 
of Coartem® [49]. Also in 2009, Novartis launched 
Coartem® Dispersible, the first pediatric formulation 
of an Artemisinin Combination Therapy (ACT) for 
children. The same drug combination (artemether- 
 
lumefantrine) is sold as Riamet® in industrialised 
countries. This differential pricing strategy ensures 
the return of investment.  
Since 2005, Novartis has been delivering fixed-
dose-combinations of anti-tuberculosis treatment in 
Tanzania with directly observed short-course 
therapy through the WHO. In 2009, Novartis 
announced plans to further extend this TB drug 
donation program [46].  
 
The Glivec® International Patient Assistance 
Program (GIPAP) provides access to Glivec®, a 
drug against chronic myeloid leukaemia for patients 
in need of it. The patient access programs range 
from full donation to a shared contribution model 
and co-pay model. It was initiated in 2002 and 
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operates in about 80 developing countries in Africa, 
Asia, Eastern Europe, South America, and the 
Caribbean that have no comprehensive 
reimbursement system or available generics [46]. 
 
The Novartis Arogya Parivar program is operating in 
20% of India’s districts and offers improved access 
to health education and affordable medicines for 40 
million people. Its approach is based on the four As: 
awareness, acceptability, affordability, and 
availability, adapted to low-income markets. The 
project focuses on the delivery of 75 medicines, 
vaccines, and micronutrient medicines that address 
12 therapeutic areas including TB, diabetes, mother 
and childhood malnutrition, and respiratory and 
gastrointestinal problems. A similar program is 
being launched in Kenya in 2011. The products are 
tailored to the villagers, simple to use, and available 
in small packages with instructions in local 
languages. The programme further supports the 
supply chain to ensure continuous supply, and it 
provides community health education to address 
low levels of disease awareness [49].  
 
Practical project and program work 
The activities in the field of practical project and 
program work, networking, and information work are 
covered by the NFSD, which is a privately 
registered NGO in Switzerland, funded by Novartis 
[36]. More details are offered in section 4.3. 
 
In addition to the abovementioned contributions to 
the implementation of the GSPA-PHI, Novartis is 
supporting different organisations and is a partner in 
different PPPs and alliances, such as, for example, 
in the PPP ACT in Zambia, ALIVE in Tanzania, and 
SMS for Life in Tanzania, as described in section 
4.5. It is also one of the many other partners in the 
Global Alliance for TB Drug Development (TB 
Alliance). The mission of the TB Alliance is to 
accelerate the discovery and development of cost-
effective new anti-TB medicines, which should 
shorten or simplify treatment, provide a more 
effective treatment of multi-drug resistant TB, and 
improve treatment of latent TB.  
Novartis does not file patents in the least developed 
countries (LDCs). This is in line with the transition 
period for LDCs to implement TRIPS regulations 
until January 1, 2016, for pharmaceutical patents. 
 
Contributions concern mainly elements 1, 2, 3, 4, 6, 
and 7 of the GSPA-PHI. 
 
4.4.2 Roche 
Roche’s corporate responsibility is reflected by a 
tradition of commitment, as stated on their 
webpage. Roche is committed to sustainability and 
thus to running the business in a way that is ethical 
and responsible and creates long-term value [50]. 
 
Roche’s approach in the world’s LDCs (as defined 
by the United Nations) is driven by the need to 
create sustainable solutions to help facilitate better 
access not only to medicines and diagnostics but to 
health care as a whole. The company has the 
following long-term strategies [51]:  
 
 have a clear patent and pricing policy for the 
medicines rather than donating products 
 build partnerships with governments, NGOs, 
and other committed parties 
 continue research and development into new 
and existing medicines in areas of unmet 
medical need 
 promote education, training, and knowledge 
sharing 
 donate technical expertise to local service 
providers and manufacturers 
 
Support for drug research 
In 2009, Roche started collaboration with the 
Institute of OneWorld Health, which allows 
OneWorld Health to screen compounds from the 
Roche library with the view of identifying new drugs 
for treating childhood diarrhoea. In a first round, 
OneWorld Health identified 40 compounds to 
investigate as possible new treatments [51]. 
 
In 2009, Roche partnered with Google.org, the 
philanthropic arm of Google.com, by donating its 
medical research and sequencing expertise to 
support a multidisciplinary surveillance, research, 
and response system for emerging infectious 
diseases in East Africa. The project focuses 
primarily on arboviruses, which frequently cause 
emergent diseases such as viral encephalitis or 
hemorrhagic fever [52].  
Access programs 
Roche Diagnostics’ HIV viral load test has become 
the gold standard for monitoring the efficacy of HIV 
treatment. Since 2002, the AmpliCare initiative has 
made these tests available at the lowest possible 
price in sub-Saharan Africa, South America, and the 
LDCs most affected by HIV and AIDS, along with 
education programmes to support the use of tests 
and treatments. Roche Diagnostics works in 
partnership with international agencies, local 
communities, hospitals, and the Clinton Foundation. 
 
Recently, Roche Diagnostics started a partnership 
with the Clinton Foundation to improve access to 
HIV testing for infants in 35 countries in sub-
Saharan Africa by providing molecular-based HIV 
infant diagnostic tests in combination with dry blood  
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spot methodology, which are used to diagnose HIV 
in children younger than 18 months [51]. 
 
Other initiatives to increase access to laboratory 
services include, for example, the development of 
screening techniques for TB and resistant strains 
[51].  
 
The Phelophepa Health Care Train is a mobile clinic 
with 16 coaches to supply general, dental, eye, and 
psychiatric care to rural South Africa. The train 
provides primary health care to about 40,000 
patients a year and is staffed by 14 health 
professionals and 40 student volunteers. The 
project started in 1994, and Roche is the main 
sponsor. Recently, cancer education and the 
screening process were enhanced as a service [51]. 
 
Two HIV medicines are supplied at a non-profit 
price to the LDCs and sub-Saharan Africa. Since 
2007, Roche has offered Valcyte® (valganciclovir) 
at a substantially reduced price to the international 
NGOs treating AIDS-related cytomegalovirus 
infection in all low- and lower-middle income 
countries [51]. 
 
In collaboration with Novo Nordisk, the World 
Diabetes Foundation, and governments, Roche is 
running a project aimed at improving the lives of 
children with diabetes in developing countries. In 
addition to access to treatment, the project focuses 
on sustainable diabetes care including awareness 
building, screening, education, and training for 
health care workers, patients, and their families [51]. 
 
In 2009, Roche launched the Tamiflu® Reserves 
Programme for developing countries. Roche will 
produce and store Tamiflu® pandemic stockpiles for 
specified9 developing countries at a significantly 
reduced price with the cost spread over a number of 
years. Furthermore, Roche renewed sub-license 
contracts for the production of Tamiflu® in China, 
India, and specified developing countries. In 
                                                     
9 Countries that are members of the Global Alliance for Vaccines and 
Immunization (GAVI) 
addition to its donations of Tamiflu® to the WHO 
from 2004–2005, Roche announced in 2009 another 
donation of Tamiflu® to WHO to replenish their 
pandemic stockpiles [51]. Overall, Roche has 
donated over 5 million packages of Tamiflu® to 
WHO. 
 
Skills transfer/education 
Roche is supporting many different training and skill 
transfer programmes, many of which not only 
provide skill transfer but also support local health 
care infrastructure in a broader sense. 
 
For three years, Roche has supported physicians 
from the Albert Einstein College of Medicine to train 
over 200 Ethiopian doctors, nurses, clinical officers, 
and final-year medical students by addressing the 
greatest educational needs of local health workers 
such as complications in pregnancy and childbirth or 
treatment of infectious diseases.  
 
EDUCARE (EDUcation for Cancer in African 
REgions) is a PPP between Roche and the 
International Atomic Energy Agency (IAEA) to 
improve training in cancer care for health care 
workers in sub-Saharan Africa [53]. EDUCARE aims 
to reach over 200 health care workers in the first 
year of the programme. The programme will initially 
focus on four pilot countries: Ghana, Tanzania, 
Uganda, and Zambia. Roche has committed to a 
five-year plan. 
 
Since 2007, Roche has been sponsoring 
pharmacists and doctors from LDCs to spend 
between three and six months at a Roche clinical 
pharmacology unit with the aim that the trainees will 
be able to manage clinical trials in their own 
countries afterwards.  
 
In South Africa, Roche has formed a partnership 
with the National Institute for Communicable 
Diseases to establish the ‘PCR Academy’ with the 
aim of addressing the skills shortage in molecular 
biology laboratories by providing accredited training 
programmes and improving quality control.  
 
Roche supports the WHO's Division for Tropical 
Diseases to train researchers, clinical monitors, and 
ethics committees in compliance, good clinical 
practice, and quality assurance. For instance, it has 
carried out a series of workshops for researchers 
managing and monitoring WHO-sponsored trials on 
tropical diseases.  
 
Since 2006, Roche has a Secondment Policy to 
enable its employees to contribute their skills and 
expertise to help developing countries for a duration 
of 3 to 18 months [51].  
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In 2006, Roche commenced the ‘AIDS Technology 
Transfer Initiative’, designed to help local 
manufacturers in countries with limited resources to 
manufacture generic versions of HIV medicines. It 
aims, through sharing of know-how, to increase 
local capacity to be able to provide treatment and to 
decrease reliance on wealthier nations. Knowledge 
and skills transfer is done at local manufacturers’ 
production sites with on-site training provided by 
experienced Roche teams [51]. In addition, Roche 
has also granted knowledge transfer to a South 
African manufacturer for the provision of generic 
Tamiflu® for pandemic use on the African sub-
continent. 
 
Roche has developed an electronic interactive 
education tool on the basics of genetics for 
physicians, scientists, students, and educators, 
which is available on-line or as CD-ROM in 11 
languages and is distributed free of charge for 
educational purposes.  
In addition to the abovementioned contributions to 
the implementation of the GSPA-PHI, Roche is a 
partner in different PPPs such as the Accelerating 
Access and the Cambodian Treatment Access 
Programme. More details are given in sections 4.5.1 
and 4.5.2. of this report.  
 
Roche’s clinical trials policy 
Roche’s clinical trials policy10 for low- and middle-
income developing countries was adopted in 2005. 
It states that Roche will not conduct clinical studies 
in such countries solely for the purposes of 
registering the drug in another country, meaning not 
performing clinical trials in countries where the 
company will not seek marketing approval. 
Patent and pricing policies 
Since 2001, Roche has applied the following patent 
policy: Roche does not file for new patents on any 
Roche medicines, for any disease, in LDCs defined 
by the United Nations (UN)11. Nor does Roche 
enforce existing patents in these countries. This 
means generic versions of any Roche medicine can 
be produced and distributed in the LDCs without 
applying for a license. 
Not all countries in sub-Saharan Africa, the region 
hardest hit by HIV/AIDS, are defined as LDCs. 
Roche’s policy is not to file patents on any new 
antiretroviral treatments for HIV/AIDS12 in the 
hardest-hit region, sub-Saharan Africa, nor to 
enforce existing patents, thus including countries 
that are not defined as LDCs. In 2010, Roche 
expanded this policy to include the low-income 
                                                     
10 Roche clinical trials policy for low- and middle-income countries available at 
http://www.roche.com/clinical_trials.htm 
11 Roche’s statement available at 
http://www.roche.com/medical_value_patents_and_pricing.htm  
12 Roche’s research into new HIV/AIDS medicines was discontinued in 2008. 
countries defined by the World Bank, thus covering 
another six countries. 
 
In 2008, Roche adopted a position on pricing13 
including six guiding principles. Principle No. 6 
states that to respond to the social responsibility of 
providing and improving access to products and 
services, especially in less affluent economies, 
Roche is assessing the structure and feasibility of 
special pricing schemes. Roche considers 
preferential pricing schemes in low and lower-
middle income countries (as defined by the World 
Bank) for diseases that are deemed key priorities by 
appropriate supra-national institutions. The 
differential pricing policy already applied in the 
Roche AmpliCare programme (see above) is being 
extended to include other neglected diseases for 
which Roche may have applicable diagnostic 
solutions. 
 
Contributions concern mainly elements 1, 2, 3, 4, 6, 
and 7 of the GSPA-PHI.  
 
4.4.3 The contribution of the private for-profit 
sector to the elements of the GSPA-PHI 
Although the main focus of the private for-profit 
sector is not on health issues in low-resource 
settings, both Novartis and Roche have 
programmes and activities supporting the 
implementation of the GSPA-PHI across most of its 
elements. These programmes and activities are part 
of the corporate responsibility of the private industry.  
 
Novartis implements these programmes and 
activities in a blended approach that combines 
direct and indirect involvement. Programmes with 
direct involvement are, for example, the Malaria 
Initiative program and Arogya Parivar; more indirect 
involvement is reflected through the programmes of 
NVGH or NFSD, both institutions set up and funded 
by Novartis. Roche seems mostly to be directly 
involved in specific projects. Both Novartis and 
Roche are also partners in various PPPs. 
 
The private industry does not prioritise and promote 
research and development needs of low-income 
countries in a direct way; rather, they do it through 
other channels, such as through the NVGH, which 
was set up by Novartis, or through facilitating 
access to compound libraries such as the 
collaboration between Roche and OneWorld Health. 
These activities contribute to elements 1 and 2 of 
the GSPA-PHI. 
 
Roche’s contribution to elements 3 and 4 is 
manifested through the technology transfer initiative 
                                                     
13 Roche Position on Pricing available at 
http://www.roche.com/medical_value_patents_and_pricing.htm  
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and several specific capacity-building and skill 
transfer programmes. Novartis contributes to these 
elements mostly through its non-profit institutes with 
NITD having a strong capacity-building component.  
 
Roche and Novartis consider themselves as 
contributing to element 5 because they are not filing 
any patents for pharmaceutical products in LDCs. 
This is in line with the transition period for the 
implementation of the TRIPS regulation for LDCs 
until January 1, 2016.  
 
Both companies have a range of activities 
supporting access to treatment and therefore the 
implementation of some activities of element 6. 
Activities include, for example, the application of 
differential pricing policies such as for the 
antimalarial medicine Coartem® by Novartis, for the 
two HIV medicines by Roche, and by Roche’s 
AmpliCare Initiative.  
 
Through channelling of funds to health-oriented 
research institutions and through the support of 
PPPs and PDPs, the for-profit private sector is also 
contributing to element 7 of the GSPA-PHI. 
 
4.5 The Private–Public Partnerships 
Over the last few years, partnerships between 
public and private sector organisations have 
become an increasingly common mechanism to 
address some of the diseases of the poor in 
developing countries [54]. Current evidence shows 
that PPPs have a beneficial effect by increasing the 
number of products in development, greater 
funding, the potential for lower costs, a reduced time 
to market, and improved availability of and access 
to products, as well as for an improved health 
impact and higher innovation levels [55]. PPPs bring 
together skills, knowledge, and resources from a 
variety of sectors including academia, 
nongovernmental organisations, philanthropists, 
government, and intergovernmental agencies, as 
well as members of the for-profit private sector such 
as pharmaceutical and biotech companies to create 
a unique approach to solving global health 
challenges [54].  
 
Each partnership has its own characteristics, and 
the variety of the PPPs makes a common definition 
difficult; therefore, no generally recognised definition 
exists. The working definition used in the context of 
this assessment is as follows: a PPP is a 
cooperative venture between the public and private 
sector, built on the expertise of each partner that 
best meets clearly defined public needs through the 
appropriate allocation of resources, risks, and 
rewards [56].  
 
In the context of this assignment, where the 
contribution of Switzerland to the implementation of 
GSPA-PHI will be described, the PPPs must have a 
Swiss component. Therefore, at least one of the 
partners contributing to the PPP should be a Swiss 
company or institution. The Swiss contribution can 
be either financial, or operational, or intellectual, 
where, for example, Swiss experts are on the board 
of a global PPP, or can be a combination of these 
categories.  
 
This assessment has identified a total of 18 PPPs 
corresponding to the above definition. Basically, the 
PPPs can be classified into two categories, namely 
into global/international PPPs and local/national 
PPPs. While the global PPPs listed in the frame of 
this mandate have a broad aim and focus on low-
resource settings in general (or diseases endemic 
areas), the local PPPs have a mission with a more 
narrow focus on activities for a specific country.  
 
In the following paragraphs, an overview of the 18 
identified global and local PPPs is presented. The 
contributions of the larger programs such as MMV, 
DNDi, and the NITD, for example, are presented as 
a summary of the initiative rather than describing 
each individual project.  
 
4.5.1 Global/International PPPs 
 
Accelerating access initiative (AAI) 
AAI is a partnership between UNAIDS, WHO, 
UNICEF, UNFPA, the World Bank, and five 
research-based pharmaceutical companies founded 
in 2000. One of the pharmaceutical companies 
involved since the beginning is Roche. Four other 
pharmaceutical companies joined the initiative later. 
The partnership is committed to working with 
governments, international organisations, and other 
stakeholders to find ways to broaden access while 
ensuring rational, safe, and effective use of 
medicines for HIV and AIDS. The commitment is to 
provide antiretroviral drugs at about 10% of the 
commercial price to the public and nongovernmental 
sector [57, 58]. Contributions mainly concern GSPA-
PHI element 6. 
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Buruli Vaccine Research Project (BuruliVac) 
The BuruliVac consortium started to operate in 
March 2010 with the aim of identifying and 
developing novel vaccine candidates against Buruli 
Ulcer disease suitable for translation into clinical 
application. A multidisciplinary approach is used, 
focusing on basic and applied research in 
immunology, bioinformatics, molecular genetics, 
tropical medicine, microbiology, and clinical 
bacteriology. The project also involves extensive 
technology transfer, training activities, and human 
capacity building. The research project is funded by 
the European Union; the Swiss TPH, as one of the 
fifteen partners, provides scientific input [59]. 
Contributions mainly concern GSPA-PHI elements 
1, 2, 3, and 4.  
 
Consortium for parasitic drug development (CPDD) 
The non-profit consortium was set up in 2000 to fill a 
gap in the discovery and development of new drugs 
for the treatment of specific neglected diseases with 
a focus on sleeping sickness and visceral 
leishmaniasis. All members are scientists and 
clinicians from academic and not-for-profit 
organisations. The work areas include a whole 
range of activities from early lead optimisation up to 
clinical trials and registration; during the later 
phases of the drug development process, 
partnerships with industry and global institutions are 
sought. The CPDD also offers a grant program 
providing funds to individual investigators for 
promising new research approaches. Resources are 
shared between CPDD members and investigators. 
The Swiss TPH acts as one of fifteen consortium 
members providing scientific input [60].  
Contributions mainly concern GSPA-PHI elements 
1, 2, 3, and 4. 
 
Drugs for Neglected Diseases initiative (DNDi) 
DNDi was founded in 2003 as an independent, not-
for-profit PDP working to research and develop new 
and improved treatments for neglected diseases 
such as leishmaniasis, sleeping sickness, Chagas 
disease, and malaria. DNDi mainly consists of 
public partners but also closely collaborates with the 
international research community, the 
pharmaceutical industry, and other organisations to 
bridge the existing R&D gaps to find essential drugs 
for these diseases. DNDi also has a strong focus on 
supporting existing capacity in countries where the 
diseases are endemic. 
 
DNDi contributes on different levels to the 
implementation of the GSPA-PHI through the 
following: 
 
 Implementation of research projects. Since its 
start in 2003, more than 350 research, 
technical, or funding agreements have been 
signed. The current portfolio includes 18 
projects in the field of drug discovery, 
preclinical, and clinical studies and medicines 
available to patients.  
 Technology transfer in low-resource settings.  
 Advocacy efforts for improved access to 
medicines.  
 Decisions on patent ownership/licensing terms 
on a case-by-case basis through its own 
intellectual property policy guide for R&D 
activities ensuring affordable treatments, 
equitable access to treatment, and drugs as 
public goods. 
 Adapting drug regulations, including drug 
registration processes, to the particular needs 
of developing countries. 
 
DNDi’s Swiss component includes an intellectual 
contribution with two Swiss experts serving on the 
board of directors, and financial contributions from 
SDC and the Canton of Geneva [61, 62]. 
Contributions mainly concern GSPA-PHI elements 
1, 2, 3, 4, 5, 6, and 7. 
 
European Malaria Vaccine Development 
Association (EMVDA) 
EMVDA, set up as a five-year project starting in 
2008, aims at systematically developing and testing 
vaccines against malaria by comparative and 
continuous evaluation of candidates. The Swiss 
TPH is a member of the consortium. EMVDA closely 
collaborates with public and private partners. The 
EMVDA has established a Research Reagent 
Repository with the aim of sharing useful reagents 
for the development of malaria vaccines among 
members of the EMVDA Consortium members. Key 
activities comprise vaccine research and 
development and production, training and 
partnership activities for African partners, and 
product management [63]. 
Contributions mainly concern GSPA-PHI elements 
1, 2, 3, and 4. 
 
Medicines for Malaria Venture (MMV) 
MMV is a not-for-profit PPP founded in 1999. Its 
main mission is to reduce the burden of malaria in 
disease-endemic countries by discovering, 
developing, and facilitating delivery of new, 
effective, and affordable antimalarial drugs through 
PPPs. Today, MMV works in partnership with more 
than 80 research institutions and companies around 
the world, mainly in the United States, Australia, and 
Europe and with universities in South Africa and 
Contract Research Organisations in India [64].  
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Key characteristics/activities of MMV are as follows: 
 
 Implementation of research projects: At the end 
of 2009, the MMV portfolio included a range of 
32 projects in the fields of lead generation, lead 
optimisation, preclinical studies, Phase I, Phase 
IIa/IIb, and Phase III studies, drug registration, 
and Phase IV. Two of the current projects are in 
the registration process (Dihydroartemisinin-
Piperaquine (Eurartesim™/sigma-tau) and 
Pyronaridine-Artesunate (Pyramax®/Shin 
Poong Pharmaceuticals), and two medicines 
have already reached the market—
Coarsucam®/sanofi aventis developed together 
with DNDi and Coartem® dispersible/Novartis—
both of them WHO pre-qualified and approved 
in several countries.  
 Implementation of clinical trials in the disease-
endemic countries in collaboration with local 
universities sharing expertise and technologies.  
 Development of strategies to improve access to 
and uptake of medicines through support of 
product adoption, expansion, and product 
development. 
 Implementation of the MMV intellectual property 
policy. Final decisions about patenting and 
licensing are made on a case-by-case basis, 
following the principle of ensuring wide access 
to the newly developed medicine according to 
their public health mission.  
 MMV recently joined the pool for open 
innovations against neglected tropical diseases, 
which was started by GlaxoSmithKline in 
February 2009. This pool was established by 
GlaxoSmithKline in February 2009 with the aim 
of motivating innovative and efficient drug 
discovery and development by opening access 
to intellectual property or know-how in the field 
of product development for the treatment of 
neglected tropical diseases. The pool is outlined 
by two core principles that (1) include 
therapeutics to treat the 16 neglected tropical 
diseases as defined by the FDA (TB, malaria, 
blinding trachoma, buruli ulcer, cholera, 
dengue/dengue haemorrhagic fever, 
dracunculiasis, fascioliasis, human African 
trypanosomiasis, leishmaniasis, leprosy, 
lymphatic filariasis, onchocerciasis, 
schistosomiasis, soil transmitted helminthiasis, 
and yaws) and (2) will be royalty free for sales 
in the world’s least developed countries as 
defined by the United Nations [65].  
 
MMV receives funding from SDC; furthermore, one 
of the founding members is the current director of 
the Swiss TPH, Marcel Tanner [64].  
Contributions mainly concern GSPA-PHI elements 
1, 2, 3, 4, 5, 6, and 7. 
NGBS program in malaria drug discovery 
This program, set up in 2006, aims at developing 
medicines for malaria treatment. Among the 
members of the consortium are the Swiss TPH and 
the NITD. The program has its own pipeline with 
projects ranging from target identification through 
lead optimisation to preclinical studies. 
Contributions mainly concern GSPA-PHI elements 1 
and 2. 
 
Novartis Institute for Tropical Diseases (NITD) 
NITD was set up as a PPP between Novartis and 
the Singapore Economic Development Board in 
2002. The institute aims to discover novel 
treatments and prevention methods for major 
tropical diseases with a focus on dengue, TB, and 
malaria. In developing countries where these 
diseases are endemic, Novartis makes treatments 
readily available for poor patients without profit. 
Activities include the fields of target discovery, 
screen development, compound optimisation, 
preclinical development, and proof-of-concept 
clinical trials; their implementation is based on 
global partnerships. In 2009, the portfolio included 
an estimate of 20 different projects for the three 
target diseases [66].  
The Swiss component comprises Novartis as an 
international company with Swiss roots as one of 
the partners and also intellectual contributions that 
are offered by a leading Swiss expert who is part of 
the scientific board of the institute.  
Contributions mainly concern GSPA-PHI elements 
1, 2, 3, 4, 5, and 7. 
 
PF1022A Consortium 
The three-year partnership between the Swiss TPH 
and Bayer AG is based on a Memorandum of 
Understanding and targets the further development 
of PF1022A, a substance with anthelmintic activity 
that is currently used in cats, to make it available for 
the use in humans.  
Contributions mainly concern GSPA-PHI elements 1 
and 2. 
 
Tribendimidine Consortium 
The aim of this consortium that started in 2007 is to 
further develop the anthelmintic drug tribendimidine 
to reach worldwide availability and distribution. 
Currently, tribendimidine is only available in China. 
In this consortium, the Swiss TPH is partnering with 
OneWorldHealth and a Chinese pharmaceutical 
company.  
Contributions mainly concern GSPA-PHI elements 1 
and 2. 
 
4.5.2 Local PPPs 
In addition to the global PPPs, there are also 
several more locally acting PPPs with activities that 
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are mostly limited to one country. A short overview 
is presented in the following list: 
 
 ACCESS in Tanzania, focusing on improved 
malaria treatment; Swiss partners are the NFSD 
and the Swiss TPH. 
 ACT treatment for malaria in pregnant women 
in Zambia; the Swiss partner is Novartis. 
 ALIVE for malaria treatment in Tanzania; Swiss 
partners are the Swiss TPH, NFSD, and 
Novartis. 
 Cambodian Treatment Access Programme (in 
the field of HIV); the Swiss partner is Roche. 
 Accès initiative in Mali to strengthen the 
national health system at the primary level; the 
Swiss partner is the NFSD. 
 NATNETS in Tanzania to promote the national 
use of insecticide-treated nets by making nets 
affordable, accessible, and acceptable; Swiss 
partners are the Swiss TPH and SDC.  
 SMS for Life in Tanzania is a partnership that 
deploys SMS technology to significantly reduce 
health facility stock-outs, thereby leading to 
improved access to essential medicines; Swiss 
partners are Novartis and SDC. 
 The Tanzanian Training Centre for International 
Health (TTCIH), aiming to be among the leading 
public health training centres; Swiss partners 
are the NFSD and the Swiss TPH. 
 
4.5.3 Contributions of the PPPs to the 
different elements of the GSPA-PHI 
Overall, it can be stated that PPPs with a Swiss 
involvement are contributing to all GSPA-PHI 
elements except element 8, which is addressed only 
by WHO and the government. This level of 
contribution is achieved through a diversified range 
of individual activities as indicated by involvement in 
the abovementioned initiatives, consortia, programs, 
and projects.   
 
PPPs have become a popular mechanism to 
address research and development needs focusing 
on neglected diseases. Because the 
abovementioned PPPs were set up with a focus on 
research and development needs of developing 
countries, they are all contributing to many activities 
given in elements 1 and 2 of the action plan, which 
are focused on prioritising and promoting research.  
It has to be highlighted that the PPPs that are listed 
here in the context of this assignment follow the 
“Global Access Strategy”, especially DNDi, MMV, 
and NITD, and therefore contribute substantially to 
element 2.4.d of the action plan, which recommends 
further development and dissemination of publicly or 
donor-funded medical interventions and know-how 
through appropriate licensing policies. The “Global 
Access Strategy” is driven by the public health 
interest, ensuring the application of the most 
appropriate patent filing and licensing strategy in 
each case. This can include the decision not to file 
any patent or to file a patent and then clearly define 
license agreements that ensure optimal access to 
the medicine for use in the public health sector in 
low-resource settings.  
 
Many PPPs participate in programs of applied 
research in collaboration with local partners, such 
as MMV, DNDi, NITD, BuruliVac, and many others. 
These collaborations support not only the exchange 
of knowledge and therefore the contribution to 
element 3, the building and improving of innovative 
capacity, but also the transfer of technology, which 
is reflected in element 4.  
 
A contribution to element 5 is limited; however, it 
includes encouraging and supporting the application 
and management of intellectual property in a 
manner that maximises health-related innovation 
and also includes capacity building of national and 
regional institutions in this area. As already 
mentioned above, the PPPs listed here follow the 
“Global Access Strategy”. 
 
Many of the local PPPs have a stronger focus on 
the implementation of research results and policy 
development than on research activities 
themselves, such as, for example, NATNETS and 
the different access programs, and therefore have 
their main contribution to the implementation of the 
GSPA-PHI in the activities of element 6, related to 
improved delivery and access.  
 
DNDi, MMV, and NITD are not only set up as PPPs 
but also are partners in many different PPPs and 
PDPs and therefore contribute to sub-element 7.2.c 
of the GSPA-PHI, which is described as supporting 
public–private and product development 
partnerships and other appropriate research and 
development initiatives in developing countries. 
 
 
© FDFA, Presence Switzerland 
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Table 1: Overview of the contribution of different sectors to the implementation of the GSPA-PHI  
GSPA-PHI: Framework for needs-driven research focusing on target diseases; plan of action according to 8 different elements and over 100 specific activities 
Federal Offices Academic Sector NGOs Private For-Profit Sector PPPs
SER: Contributing to elements 
1,2,3,4 and 6; mostly through 
funding support 
 
SDC: Contributing to elements 
1,2,3,4 and 6; support to health 
projects in bilateral cooperation, 
support to the policy dialogue, 
and funding support 
 
SECO: Contributing to 
elements 3 and 4; support in 
the field of infrastructure, 
collaboration with IPI 
 
FOPH: Contributing to 
elements 1,3,5,6, and 8; 
financial support, capacity 
building, advocacy at national 
and international level 
 
IPI: Contributing to elements 2 
and 6, and most relevant 
contribution to element 5 
 
Swissmedic: Contributing to 
elements 3 and 6 
Contributing to element 1, 2 
and 3 through different 
research partnerships and 
networks, such as NCCR 
North-South, RPDC, 
SCOPES, SNIS, supported by 
SNSF, SDC, and SER 
 
Specific programmes or 
institutes, such as SMIH, GHI, 
and Swiss TPH with main 
focus on improving innovation 
and access in low resource 
settings, contributing to 
element 4 and 5 
 
Open access to knowledge 
and technology (activity 2.4.a) 
Main actors are BD, MSF 
Switzerland, mediCuba-Suisse, 
SRC, NFSD; as a whole, NGOs 
are contributing to all elements 
except for element 8 
 
Contribution to R&D in the field 
of traditional medicine 
 
Strong emphasis on capacity 
building, strengthening health 
surveillance and information 
system through local presence; 
interlinking of on-site 
programmes with political 
advocacy 
 
Contribution to element 6 
through participation in 
programmes of applied research 
Contribution to elements 1, 2, 3, 4, (5), 6, 
and 7; these activities and programmes 
are part of the corporate responsibility 
Contribution to the elements 1, 2, 
3, 4, 5, 6, and 7; popular 
mechanism to address research 
and development needs focusing 
on neglected diseases 
Novartis
Direct involvement in 
specific projects (e.g. 
technology 
transfer/educational 
programs), indirect 
contribution through 
the set up and 
funding of non-profit 
institutions such as 
NVGH, NITD, NFSD 
 
Differential pricing 
and full donation 
access programmes 
for medicines for 
malaria, several 
cancers, leprosy, 
fasciolasis and TB 
 
Partner in various 
PPPs 
Roche
Direct 
involvement in 
specific projects, 
especially in the 
field of capacity 
building and 
technology 
transfer 
 
Differential 
pricing access 
programme for 
two HIV 
medicines and 
HIV monitoring 
tests 
 
Partner in 
various PPPs 
Global PPPs
Main 
contribution to 
element 1 and 
2; research and 
development  
focusing on 
diseases in 
endemic areas 
 
Global Access 
Strategy 
contributing to 
activity 2.4d 
 
Applied re-
search in 
collaboration 
with local 
partners, 
contributing to 
element 3 and 
4 
Local PPPs 
Focusing on 
activities for a 
specific 
country, 
implementation 
of research 
results, 
contribution to 
element 6 
Elements: 1- Prioritizing research and development needs 2- Promoting research and development 3- Building and improving innovative capacity 4- Transfer of technology 5- Application and management 
of intellectual property to contribute to innovation and promote public health 6- Improving delivery and access 7- Promoting sustainable financing mechanism 8- Establishing monitoring and reporting 
systems. 
Activitiy 2.4a: Promote the creation and development of accessible public health libraries in order to enhance availability and use of publications by universities institutions and technical centres, especially 
in developing countries. 
Activity 2.4d: Encourage the further development and dissemination of publicly or donor-funded medical inventions and know-how trough appropriate licensing policies, including but not limited to open 
licensing, that enhance access to innovations for development of products of relevance to the public health needs of developing countries on reasonable, affordable and non-discriminatory terms.
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5 Discussion 
The assessment of activities of five major sectors, 
namely the federal offices, the academic sector, the 
NGOs, the private for-profit sector, and the PPPS, 
reflects that Switzerland is contributing to every one 
of the key elements of the GSPA-PHI. Key activities 
and contributions of the different sectors are 
summarised in Table 1. 
 
This general statement, however, needs to be 
qualified with several important remarks. 
 
5.1 Limitation of the current assessment 
It is important to highlight that inevitably, by the 
nature of the approach and the available resources, 
this review and assessment of Swiss activities 
related to the GSPA-PHI has some limitations in 
relation to the following: 
 There is a lack of knowledge of the GSPA-PHI 
strategy by some key informants, influencing 
the level of detail and completeness of the 
provided information; therefore, the list of 
described activities cannot be claimed to 
be exhaustive and complete. 
 The heterogeneous level of information and the 
engagement of Swiss actors with respect to the 
IGWG with concomitant lack of resources made 
it difficult to collect all necessary information. 
 There are possible overlaps in reported 
activities because of joined efforts between the 
different actors. 
 There is a lack of clear definitions regarding 
Swiss PPPs and the contribution and 
involvement of Switzerland in this sector 
towards the implementation of the GSPA-PHI. 
 A quantification of the state of the 
implementation was not feasible based on the 
collected information. 
 
The assessment showed that the complexity of the 
domain covered by the GSPA-PHI limited a 
comprehensive country-level analysis. There are 
numerous areas of overlap between the elements 
and their activities. In addition, the activities 
reported by the different projects and initiatives are 
often multipurpose and multidisciplinary and cover a 
wide range of issues pertaining to different 
elements. As a result, the appropriate attribution of 
the information to clearly defined activities of the 
action plan became partly arbitrary. As mentioned 
above, the understanding of the interventions 
relevant to each particular element varied within 
stakeholders. As a result, many projects and  
 
 
 
 
initiatives were being attributed to a range of 
different activities.  
 
Therefore, Appendix 1 reflects stakeholders’ 
contributions and embeds the abovementioned 
limitation.  
5.2 Conscious effort and systematic 
approach needed 
The fact that Switzerland contributes essentially to 
each of the key elements of the GSPA-PHI is not 
always the result of a conscious effort and a 
systematic approach, but simply a reflection that 
many Swiss actors are active in this field and take 
the challenges serious. Several actors have very 
interesting initiatives and projects, but there is little 
evidence of information or lessons learnt being 
exchanged proactively. For instance, the Swiss 
delegation participating in the negotiation process of 
the GSPA-PHI could not be aware of the different 
activities of Swiss actors because no systematic 
survey had been conducted before. This lack of 
exchange of information may lead to scarce 
complementarities and even unnecessary 
duplication of activities, which this report could help 
to overcome. 
 
Current evidence shows that PPPs have a 
beneficial effect by increasing the number of 
products in development, attracting funding, and 
synergising expertise. Their potential, however, for 
leading to lower costs, reduced time from 
development to market, improved availability and 
access, and improved health impact and higher 
innovation levels has yet to be demonstrated. The 
latter should be the subject of further research to 
support the Swiss decision-makers or researchers 
in the priority setting and distribution of financial and 
other support to PPPs with scientific evidence.  
 
There would be a clear benefit to be expected from 
a greater coherence of the Swiss activities 
concurring in the implementation of the GSPA-PHI 
through a well-conducted, multi-disciplinary, multi-
sector, and multi-partner approach. 
 
5.3 Trends in the contribution and identified 
gaps  
Despite the abovementioned weaknesses in the 
present assessment, some trends in the current 
contributions to the implementation of the GSPA-
PHI can be identified.  
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Swiss contributions can be found across all eight 
elements of the GSPA-PHI with many actors 
concentrating on two or three elements, some on 
only one, and some on several; only the 
government addresses all eight elements because 
element 8 is addressed only by WHO and the 
government. 
 
Some elements receive little, if no attention. In 
particular, PPPs and the private for-profit sector, 
according to the information provided in this 
assessment, are not active in the field of traditional 
medicine in relation to the implementation of the 
GSPA-PHI, and the academic sector has only a 
limited involvement. On the other hand, other Swiss 
stakeholders, namely the NGOs, appear to act as 
pathfinders in supporting the sustainable 
development and use of traditional medicine, taking 
into account the indigenous knowledge and social 
determinants of the local populations’ health-care–
seeking paths. The Swiss examples are particularly 
relevant because, while the GSPA-PHI clearly 
recognises the importance of traditional medicine, 
there is still a need to identify actors to move its new 
agenda forward. The Swiss experience could 
provide interesting lessons for better including 
traditional medicine in striving for better access to 
health. 
 
Swiss academia collaborates with some of these 
projects by contributing technical know-how and 
expertise. For instance, Swiss TPH analyses the 
chemical components of active ingredients of the 
traditional medical products. Swiss academia also 
demonstrates creativity and concern for the health 
of poor populations not only through this 
involvement in supporting traditional medicine but 
also in numerous individual projects aimed at 
developing new technologies, new approaches to 
training of health professionals, or delivering more 
accessible and efficient health care services. These 
activities remain often scattered and unknown, as 
the health, development, and innovation decision-
makers tend to address well-known, readily 
accessible partners rather than getting into the time-
consuming effort of identifying and bringing together 
the many bilateral projects of individual researchers 
and small academic institutions or hospitals.  
 
With many Swiss universities having signed the 
Berlin declaration, the academic sector makes an 
important contribution to the promotion of open 
access to the scientific work done at the 
universities.  
The current assessment clearly shows the 
contribution of the private for-profit sector to many 
different activities supporting the implementation of 
the GSPA-PHI. As for the other sectors, it is not 
possible to quantify the contribution. Recently, 
several initiatives started, supporting increased 
access to knowledge, research results, and 
intellectual property such as the “Pool for open 
innovations against neglected tropical diseases” and 
the “Medicine patent pool”, established with the 
support of UNITAID. Concerning the “Medicine 
patent pool”, the member-companies of Interpharma 
are discussing possible collaboration. Roche is 
preparing the negotiation process [35].  
 
Overall, Switzerland enjoys a wealth of expertise 
and creativity, and any effort to build up a truly 
national response to the challenges of the GSPA-
PHI would certainly benefit from an increased 
exchange of information and improved coordination 
of the multiple Swiss initiatives, whether it is from 
academia, NGOs, or other stakeholders. There is a 
clear political will to do landscaping and the 
associated analysis of the Swiss activities related to 
the GSPA-PHI, with the commitment and interest of 
some of the major Swiss stakeholders. Innovation 
and its current landscape in Switzerland are 
complex issues that require time and the 
involvement of key informants and actors as well as 
mid/long-term political and financial support.  
 
5.4 The current policy environment in 
Switzerland related to the implementation 
of the GSPA-PHI 
Inspiring and leading a process as complex as that 
of planning and monitoring the GSPA-PHI and 
involving in the country multiple national and 
international actors needs a great deal of political 
“courage”.  
 
The engagement of the FOPH and other 
governmental actors in the CIPIH and IGWG 
processes demonstrates the growing awareness of 
Swiss policy makers of the policy challenges they 
have to address for building up a national policy 
environment supportive of internationally agreed 
principles of universal access to essential medical 
products. These efforts should be in line with a 
rational, effective, and sustainable implementation 
of the GSPA-PHI. 
 
Switzerland is both an important drug producer and 
a well-respected Official Development Assistance 
(ODA) provider. The current assessment of 
activities contributing to the implementation of the 
GSPA-PHI reflects overall relevant contributions of 
all key actors. It would be of great interest to expand 
such an assessment to also address underlying 
factors such as the Swiss policy environment and 
research culture, incentives, and disincentives 
driving these factors. This would increase the 
relevance of such an assessment and provide an 
even more powerful example and model for the 
WHO Member States, the WHO Secretariat, and the 
other stakeholders concerned.  
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5.5 The issue of sustainable financing 
Various priorities and timelines are important factors 
to take into consideration when looking at 
sustainability. The current timeline defined by WHO 
Member States for the GSPA-PHI implementation is 
2015. The WHO has to report on progress to the 
World Health Assembly every two years, and the 
next progress report is expected in 2012. However, 
while the GSPA-PHI was adopted in 2008 and 
activities of the “quick start programme” are 
currently being implemented, the core of the 
implementation activities is starting at a much 
slower pace.  
 
Sustainable financing is absolutely key to the 
success of the GSPA-PHI. As identified through the 
current assessment, the usual project timeline of 
many bilateral development agencies, many North–
South research projects, and many PPPs is only 
three to five years. However, sufficient long-term 
commitment with a longer duration than only three 
to five years is needed from the Swiss government 
and other Swiss actors to implement the GSPA-PHI 
on a sustainable basis. In general, it can be 
assumed that the sustainability question is likely to 
be shifting the existing paradigms regarding R&D 
and innovation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 Conclusions  
The current assessment of the Swiss contribution to 
the implementation of the GSPA-PHI, which was 
endorsed by the World Health Assembly in May 
2008, shows that overall, the Swiss sectors 
assessed in this report have proactively 
implemented all eight elements of the GSPA-PHI. 
This does not mean that all actors are addressing 
most or all of the eight elements, but many are 
addressing two to three elements with some actors 
addressing most of the different elements. This 
assessment identified a gap in the field of traditional 
medicine, an important domain in the GSPA-PHI, 
especially from the PPPs and from the private for-
profit sector, with only limited or dispersed identified 
interventions in this domain.  
 
Moreover, while the list of Swiss activities seems to 
be quite comprehensive, it was beyond the scope of 
the assessment to determine the weight of these, 
their resulting impact, and which one should be 
favoured or simply sustained in the future. It was 
indeed not possible to quantify the contributions or  
to conclude that Switzerland is contributing enough 
or if it should do more in certain areas. 
 
Further, the assessment was subject to a number of 
limitations, among others, the lack of a common 
methodology, shortcomings of the reporting tool, 
and to a certain extent, incompleteness in the 
reports submitted by different sectors. Therefore, 
the current list of activities reflected in this report is 
not claimed to be complete, which is 
understandable in view of the complexity of the 
subject. In addition, these limitations made the 
classification of activities and data analysis 
cumbersome if not possibly biased.  
 
Even taking the limitations into account, however, a 
voluntary coordination in terms of exchange of 
information and communication among different 
actors could enhance the synergies in respect to the 
implementation of the GSPA-PHI.  
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Epilog Swiss TPH, the mandated authors of the study 
This initial review and analysis of Swiss activities related to the GSPA-PHI was not an easy task. While the 
different Swiss stakeholders concerned were interested in the exercise, not all of them were sufficiently 
conversant with the GSPA-PHI. The heterogeneous levels of information and engagement of the different Swiss 
actors, with regards to the IGWG process and its resulting strategy, did not make it easy for the various 
organisations mandated to contribute the requested data. Also, given the short time line for the data collection, it 
was difficult to obtain sufficient and appropriate information. Therefore, the information provided in the different 
reports is certainly incomplete. Serious efforts, however, were undertaken to complete the information in the 
consolidated report. For instance, it was rather difficult to explore the various interventions of the Swiss academic 
sector. There is no central body, where relevant information is collected, and information tends to be with 
individuals, or within a given part of an institution, city, or canton, with information on their efforts and results not 
easily accessible. Reliable information from the private for-profit sector is also difficult to obtain. Industries have, 
for good reason, strong corporate identities and related communication strategies. This leads to reluctance in 
sharing some information for reasons of image, potential competition, and different interpretations of transparency 
and sharing of lessons learned. Difficulties with obtaining information from Public Private Partnerships were also 
faced in terms of finding a widely agreed upon definition, especially regarding the relevant level of Swiss 
involvement to be considered a Swiss contribution towards implementing the GSPA-PHI. 
 
The tool used to support data collection in the current assessment is based on the listing of all activities of the 
GSPA-PHI. This tool is not very user friendly for assessing country level activities. In the Swiss context it has 
proven to  
be rather difficult to use because there is a lack of common understanding of some of the defined activities. 
Furthermore, there is an apparent overlap and duplication of activities, making it difficult to classify projects and 
initiatives. The complexity of the tool increased the risk of resistance to use it, hence, the likelihood of gaps in 
data collection increased. This could be one reason why the assessment reports of the different sectors were 
partially incomplete.  
 
To clearly classify the different projects and activities in relation to the activities identified by the GSPA-PHI 
requires a minimum level of information on the projects and initiatives. This information was not always available, 
least of all for the projects and initiatives of the different sectors which were added in the consolidated report. 
Therefore, the completion of appendix 1 was done to the best knowledge of the authors but cannot be claimed as 
fully complete.  
 
It is also necessary to note that the views and ideas expressed herein do not necessarily imply or reflect the 
opinion of the authors. This report is a consolidation of activities described by different stakeholders, with each 
stakeholder having contributed to the description of activities of his/her own sector. This information could not be 
systematically verified by the authors.  
 
In conclusion, through its history of involvement with the CIPIH and the IGWG processes leading to 
the adoption of the GSPA-PHI, it can be said that Switzerland has demonstrated its ability to take a 
leadership role in the area of innovation for health. Generally, Switzerland enjoys a wealth of expertise 
and creativity, and any effort to develop a comprehensive national response to the challenges of the 
GSPA-PHI would certainly benefit from an increased exchange of information and improved 
coordination of the multiple Swiss initiatives - be they from the academia, the NGOs or other 
stakeholders. Innovation and its current landscape in Switzerland is a complex issue that requires time 
and the involvement of essential informants and actors, as well as mid/long term political and financial 
support.
Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
1 Element 1.  Prioritizing research and development needs
1.1 a (a) develop methodologies and 
mechanisms to identify gaps in 
research on Type II and Type III 
diseases and on developing 
countries’ specific R&D needs in 
relation to Type I diseases 
WHO; Governments; other relevant 
stakeholders
X X X
1. SER: support to the Swiss Vaccine Research Institute; SDC: support to TDR, COHRED and GFHR
2. Swiss TPH, GHI, and other academic institutions, are, from an academic point of view, interested to 
identify gaps.
5. MMV, DNDi, NITD: through their collaborations with scientific institutions
1.1 b (b) disseminate information on 
identified gaps, and evaluate 
their consequences on public 
health 
WHO; Governments; other relevant 
stakeholders X X X X
1. SDC: support to TDR, COHRED and GFHR; SER
2. Done through scientific publications
3. MSF Switzerland
5. Done through scientific publications
1.1 c (c) provide an assessment of 
identified gaps at different levels 
– national, regional and 
international – to guide research 
aimed at developing affordable 
and therapeutically sound 
products to meet public health 
needs 
WHO; Governments; other relevant 
stakeholders
X X X X
1. SDC: support to TDR, COHRED and GFHR; SER
2. Swiss TPH, as an academic institution, is, from an academic point of view, interested to identify gaps; 
Global Health Programme of the Graduate Institute in Geneva
3. MSF Switzerland
5. MMV, DNDi, NITD: through their collaborations with scientific institutions
1.2 a (a) set research priorities so as 
to address public health needs 
and implement public health 
policy based on appropriate and 
regular needs assessments 
Governments; regional 
organizations 
X X X X
1. SER: support to the Swiss Vaccine Research Institute; SDC: support to TDR, FOPH: proposal for national 
research programme to strengthen the research and development of new drugs and vaccines against 
neglected diseases.
2. Swiss TPH: through ist collaboration with governments and regional organizations
4. Novartis through NVGH
5. DNDi, NITD: through their collaborations with governments and regional organizations
1.2 b (b) conduct research 
appropriate for resource-poor 
settings and research on 
technologically appropriate 
products for addressing public 
health needs to combat 
diseases in developing countries
Governments; WHO; other relevant 
stakeholders (including academia, 
relevant health-related industries, 
national research institutions and 
public–private partnerships) X X X X
1. SER: support to the Swiss Vaccine Research Institute, Swiss TPH and participation in the EU Framework 
Programme on Research and Development; SDC: support to TDR and ANDI, FOPH: proposal for national 
research programme to strengthen the research and development of new drugs and vaccines against 
neglected diseases.
2. Key activity of the Swiss TPH and EPFL-GHI, University of Lausanne through EU- and WHO- funded 
projects in the field of malaria, HIV and polio-vaccine, HUG-Koirala Institute project, SNSF through NCCR 
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Appendix
Table 2: WHO Global plan of action on public health, innovation and intellectual property - Swiss federal offices interested
Contribution of Switzerland
(1.1) mapping global research and development with a view to identifying gaps in research and development 
on diseases that disproportionately affect developing countries
(1.2) formulating explicit prioritized strategies for research and development at country and regional and inter-
regional levels 
    or - ou , , an  
4. Novartis through NVGH
5. Key activities of DNDi, MMV, NITD and other global PPPs
1.2 c (c) include research and 
development needs on health 
systems in a prioritized strategy 
Governments; WHO; other relevant 
stakeholders (including academia, 
national research institutions, and 
public–private partnerships)
X X X
1. SER: support to Swiss TPH; SDC: SWAPs and contribution to national health policies
2. Swiss TPH involved in many health system strengthening programmes; Geneva Health Forum; Global 
Health Programme of the Graduate Institute in Geneva
5. MMV: access program, DNDi: policy for access 
1.2 d (d) urge the leadership and 
commitment of governments, 
regional and international 
organizations and the private 
sector in determining priorities 
for R&D to address public 
health needs 
WHO; Governments; other international 
intergovernmental organizations; other 
relevant stakeholders (including private 
sector) X X X X
1. SER: support to the Swiss TPH and participation in the EU Framework Programme on Research and 
Development; SDC: support to TDR and COHRED, FOPH: proposal for national research programme to 
strengthen the research and development of new drugs and vaccines against neglected diseases.
2. Swiss TPH: through its collaboration with governments, regional and international organizations; Geneva 
Health Forum
3. BD
5. MMV, DNDi, NITD: through their collaborations with governments, regional and international organizations 
1.2 e (e) increase overall R&D efforts 
on diseases that 
disproportionately affect 
developing countries, leading to 
the development of quality 
products to address public 
health needs, user friendly (in 
terms of use, prescription and 
management) and accessible 
(in terms of availability and 
affordability) 
Governments; WHO; other relevant 
stakeholders (including academia, 
relevant health related industries, 
national research institutions, and 
public–private partnerships) 
X X X X
1. SER: support to the Swiss Vaccine Research Institute, Swiss TPH and participation in the EU Framework 
Programme on Research and Development; SDC: support to TDR and COHRED, FOPH: proposal for 
national research programme to strengthen the research and development of new drugs and vaccines 
against neglected diseases.
2. Key activity of the Swiss TPH and EPFL-GHI; University of Lausanne through EU- and WHO- funded 
projects in the field of malaria, HIV and polio-vaccine, research projects at the University of Basel and the 
University of Geneva
4. Novartis through NVGH
5. Key activities of DNDi, MMV, NITD and other global PPPs
1.3 a (a) set research priorities in 
traditional medicine 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including academia; 
national research institutions; 
public–private partnerships; and 
concerned communities) 
X 1. SDC: Support to national research programmes in Tanzania and Mali; SER
1.3 b (b) support developing countries 
to build their capacity in 
research and development in 
traditional medicine 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including academia, 
relevant health-related industries, 
national research institutions, 
public–private partnerships) 
X X
1. SER: Support to research centres in Ivory Coast and Tanzania; SDC: Support to national research 
programmes in Tanzania and Mali
3. Support of the regional centre "Medicina Natural y Tradicional MNT" in Cuba through mediCuba-Suisse, 
mission 21, SRC
1.3 c (c) promote international 
cooperation and the ethical 
conduct of research 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders
X 1. SER: Participation in COST research programmes; SDC: Support to TDR , COHRED and GFHR
(1.3) encouraging research and development in traditional medicine in accordance with national priorities and 
legislation, and taking into account the relevant international instruments, including, as appropriate, those 
concerning traditional knowledge and the rights of indigenous peoples 
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Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
1.3 d (d) support South-South 
cooperation in information 
exchange and research 
activities  
Governments; WHO; other 
international intergovernmental 
organizations; regional organizations; 
other relevant stakeholders
X X 1. SDC: Support to TDR, ANDI, COHRED and new regional initiatives in Africa3. Esperanza Medicines Foundation, Antenna Technologies, mediCuba-Suisse
1.3 e (e) support early-stage drug 
research and development in 
traditional medicine systems in 
developing countries 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders
X X X X
1. SDC
2. Swiss TPH: involvement in research on natural substances (characterized molecules, not on herbal 
extracts themselves); Uni Basel has a research project in South Africa, screening medical plants for active 
molecules
3. mediCuba-Suisse 
5. DNDi, MMV, NITD: involvement in research on natural substances such as herbal medicines; however 
mostly focussing on the characterized molecules and not on herbal extracts themselves 
2
2.1 a a) promote cooperation 
between private and public 
sectors on research and 
development 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders 
X X X X
1. SDC: Support to TDR, COHRED and GFHR; SER; SECO
2. Swiss TPH: most of the activities are done in cooperation; SNSF: SCOPES programme; KFPE: by 
conferences or by members; Geneva Health Forum
4. Novartis through NVGH
5. DNDi, MMV, NITD: most of the activities are done in cooperation
2.1 b (b) provide support for national 
health research programmes in 
developing countries through 
political action and, where 
feasible and appropriate, long-
term funding 
Governments; regional 
organizations; WHO (technical 
assistance); other relevant 
stakeholders X X X
1. SDC: SWAPs and contribution to national health policies, support to COHRED and GFHR; SECO
2. Swiss TPH support in Tanzania, leading house scientific collaboration with South Africa, Centre Suisse de 
la Recherche Scientifique en Côte d'Ivoire
5. NITD in Singapore and Indonesia; DNDI in Malaysia, India, Brazil and Kenya
2.1 c (c) support governments in 
establishing health-related 
innovation in developing 
countries 
Governments; regional 
organizations; WHO (technical 
assistance); other relevant 
stakeholders
X X 1. SDC: SWAPs and contribution to national health policies, support to COHRED and GFHR; SECO2. Swiss TPH: support in Tanzania; SNSF: joint research projects in development cooperation programme
2.2 a (a) support discovery science, 
including where feasible and 
appropriate, voluntary open-
source methods, in order to 
develop a sustainable portfolio 
of new products 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders X X X
1. SER: WIRE study; SDC; SECO; IGE
2. Key activity of Swiss TPH; SNSF: bottom up funding; University of Lausanne through EU- and WHO- 
funded projects in the field of malaria, HIV and polio-vaccine
5. Key activities of DNDi, MMV, and NITD
(2.2) promoting upstream research and product development in developing countries 
(2.1) supporting governments to develop or improve national health research programmes and establish, 
where appropriate, strategic research networks to facilitate better coordination of stakeholders in this area 
Element 2.  Promoting research and development
2.2 b (b) promote and improve 
accessibility to compound 
libraries through voluntary 
means, provide technical 
support to developing countries 
and promote access to drug 
leads identified through the 
screening of compound libraries 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders
X X X X
1. IPI
2. Swiss TPH involved in screening of compounds in many collaborations; SNSF: bottom up funding
4. Roche through collaboration with OneWorld Health
5. DNDi, MMV, and NITD: through their collaborations with the pharmaceutical industry; 
2.2 c (c) identify incentives and 
barriers, including intellectual 
property-related provisions, at 
different levels – national, 
regional and international - that 
might  affect increased research 
on public health, and suggest 
ways to facilitate access to 
research results and research 
tools 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO and 
WTO); other relevant stakeholders
X X X
1. IPI: Legislative facilitation of access to research; SECO
2. Swiss TPH following the Global Access Policy; Uni Lausanne: cooperation with WHO 
5. DNDi, MMV, and NITD: following the Global Access Policy
2.2 d (d) support basic and applied 
scientific research on Type II 
and Type III diseases and on the 
specific R&D needs of 
developing countries in relation 
to Type I diseases 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders X X X X
1. SDC: Support to TDR; SER
2. Key activity of Swiss TPH; SNSF: bottom up approach in the DC programme; NCCR North-South; RPDC; 
EPFL-GHI; some research projects at the University of Basel and at the University of Geneva and HUG; 
University of Lausanne through EU- and WHO- funded projects in the field of malaria, HIV and polio-vaccine
4. Novartis through NVGH
5. Key activities of DNDi, MMV, and NITD
2.2 e (e) support early-stage drug 
research and development in 
developing countries 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including relevant health-
related industries, academia, 
international and national research 
institutions; donor agencies; 
development partners; 
nongovernmental organizations) 
X X X X
1. SDC: Support to TDR; SECO
2. Key activity of Swiss TPH; SNSF
4. Novartis through NVGH
5. Key activities of DNDi, MMV, and NITD
2.2 f (f) build capacity to conduct 
clinical trials and promote public 
and other sources of funding for 
clinical trials and other 
mechanisms for stimulating 
local innovation, taking into 
account international ethical 
standards and the needs of 
developing countries
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including relevant health-
related industries; academia; 
development partners; charitable 
foundations; public-private 
partnerships; nongovernmental 
organizations)
X X X X
1. SER: Participation in COST research programmes; SDC
2. Swiss TPH: conducting clinical trials in low resource settings in collaboration with local partners; SNSF 
4. Roche Training Programme
5. While DNDi and MMV are involved in clinical trials of all stages, NITD's research portfolio is involving 
proof-of-concept clinical trial
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Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
2.2 g (g) promote the generation, 
transfer, acquisition upon 
agreed terms and voluntary 
sharing,  of new knowledge and 
technologies, consistent with 
national law and international 
agreements, to facilitate the 
development of new health 
products and medical devices to 
tackle the health problems of 
developing countries 
Governments; WHO; other 
international intergovernmental 
organizations, other relevant 
stakeholders (including; academia, 
international and national research 
institution;  relevant health-related 
industries and development partners) X X X
1. SDC: Support to COHRED; SECO
2. Swiss TPH: following the Global Access Policy; Uni Lausanne: cooperation with WHO; SNSF; Universities 
signing the Berlin Declaration
5. DNDi, MMV, and NITD: following the Global Access Policy
2.3 a (a) stimulate and improve global 
cooperation and coordination in 
research and development, in 
order to optimize resources 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders X X X X
1. SER: Bilateral research program with South Africa, participation in COST research programmes; SDC
2. Swiss TPH: many activities are done in cooperation; SNSF; University of Zurich; KFPE; SCOPES; NCCR 
North-South; RPDC;Geneva Health Forum
4. Novartis through NVGH, Roche collaboration with OneWorld Health
5. DNDi, MMV, and NITD: most of the activities are done in cooperation
2.3 b (b) enhance existing fora and 
examine the need for new 
mechanisms, in order to 
improve the coordination and 
sharing of information on 
research and development 
activities 
Governments; WHO; other relevant 
stakeholders 
X X X
1. SER: Participation in COST research programmes; SDC; IGE; FOPH
2. Swiss TPH is actively involved in the Commission for Research Partnerships with developing countries 
and is member of various fora; ZHUAS: active participation in international networking; SNSF; SNIS; Global 
Health Programme of the Graduate Institute in Geneva
5. DNDi, MMV, and NITD: members of various fora
2.3 c (c) encourage further 
exploratory discussions on the 
utility of possible instruments or 
mechanisms for essential health 
and biomedical R&D, including 
inter alia, an essential health 
and biomedical R&D treaty 
Interested Governments; [WHO]; 
other relevant stakeholders 
(including nongovernmental 
organizations)
X X X X
1. SER; SDC; SECO; IPI; FOPH
2. ZHUAS: active participation in international networking; Swiss TPH; Geneva Health Forum
3. BD, MMS
5. MMV, DNDi, and NITD
2.3 d (d) support active participation 
of developing countries in 
building technological capacity  
Governments; WHO; other relevant 
stakeholders  
X X X X X
1. SDC: Support to TDR, ANDI, COHRED (new initiative in Africa)
2. Swiss TPH: Contribution through collaborations with local organizations and institutions and through 
support academic carrers; SNSF 
3. Collaboration with local staff in many NGO projects
4 R h T h l T f I itit ti
(2.3) improving cooperation, participation and coordination of health and biomedical research and 
development 
. oc e ec no ogy rans er n a ve
5. DNDi and NITD contribute through collaborations with local organizations and institutions and through 
supporting academic carrers (PhD students, etc); MMV collaborates in the South mainly with universities in 
South Africa, except for running clinical trials where it collaborates with universitites in disease endemic 
countries
2.3 e (e) promote the active 
participation of developing 
countries in the innovation 
process  
Governments; WHO; other relevant 
stakeholders  
X X X
1. SDC; SECO
2. Swiss TPH: Contribution through collaborations with local organizations and institutions and through 
support academic carrers; SNSF; Universities: hosting of PhD and post-doctorate students 
5. DNDi and NITD contribute through collaborations with local organizations and institutions and through 
supporting academic carrers (PhD students, etc); MMV collaborates in the South mainly with universities in 
South Africa, except for running clinical trials where it collaborates with universitites in disease endemic 
countries 
2.4 a (a) promote the creation and 
development of accessible  
public health libraries in order to 
enhance availability and use of 
relevant publications by 
universities, institutes and 
technical centres, especially in 
developing countries 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including academia, 
research institutions, relevant health-
related industries; nongovernmental 
organizations; publishers) 
X X 1. SER; IPI; FOPH2. Universities and academic institutions which have signed the Berlin Declaration
2.4 b (b) promote public access to the 
results of government funded 
research, by strongly 
encouraging that all 
investigators funded by 
governments submit to an open 
access database an electronic 
version of their final, peer-
reviewed manuscripts 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including academia and 
research institutions) 
X X
1. SER; IPI; FOPH
2. Universities and academic institutions which have signed the Berlin Declaration; SNSF: support of open 
access
2.4 c (c) support the creation of 
voluntary open databases and 
compound libraries including 
voluntary provision of access to 
drug leads identified through the 
screening of such compound 
libraries 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO); other 
relevant stakeholders (including 
relevant health-related industries) X X X
1. SER; IPI; FOPH
2. SNSF
4. Roche through its collaboration with OneWorld Health.
(2.4) promoting greater access to knowledge and technology relevant to meet public health needs of 
developing countries 
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1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
2.4 d (d) encourage the further 
development and dissemination 
of publicly or donor-funded 
medical inventions and know-
how through appropriate 
licensing policies, including but 
not limited to open licensing, 
that enhance access to 
innovations for development of 
products of relevance to the 
public health needs of 
developing countries on 
reasonable, affordable and non-
discriminatory terms 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including academia and 
national research institutions)
X X X
1. IPI
2. Swiss TPH: Intellectual property issues are in general dealt with on a case by case basis; the basic 
guiding principle is to follow the Global Access Policy; ZHUAS: Cooperation project with Health Sciences 
University of Mongolia
5. DNDi, MMV, and NITD: following the Global Access Policy  
2.4 e (e) consider, where appropriate, 
use of a “research exception” to 
address public health needs in 
developing countries consistent 
with the Agreement on Trade-
Related Aspects of Intellectual 
Property Rights 
Governments; 
X 1. IPI: Adoption of research exemption; SECO
2.5 a (a) develop and coordinate a 
research and development 
agenda 
Governments; regional organizations; 
WHO; other relevant stakeholders X X X
1. SER; SDC
2. Swiss TPH; EPFL-GHI; ZHUAS; SNSF
5. Key activities of DNDi, MMV, and NITD
2.5 b (b) facilitate the dissemination 
and use of research and 
development outcomes 
Governments; regional organizations; 
WHO; other relevant stakeholders X X X
1. SER; SDC
2. Scientific publications
5. Publication of results
3
3.1 a (a) support investment by 
developing countries in human 
resources and knowledge 
bases, especially in education 
and training including in public 
health
Governments; other international 
intergovernmental organizations; other 
relevant stakeholders (including 
development partners)
X X X X
1. SDC: Support to TDR; SECO
2. Swiss TPH world-renowned institution for teaching and training; ZHUAS: Cooperation project with Health 
Sciences University of Mongolia; University of Basel with research projects in collaboration with the Swiss 
TPH; projects of HUG (RAFT, training in Bamako); SNSF: in the framework of the SCOPES programmes; 
Graduate Institute Geneva
Element 3. Building and improving innovative capacity
(3.1) building capacity of developing countries to meet research and development needs for health products 
2.5 establishing and strengthening national and regional coordinating bodies on research and development 
 
3. Many NGOs involved in training activities
4. Roche skills transfer and education support programmes, NVGH strong focus on capacity buidling
3.1 b (b) support existing and new 
research and development 
groups and institutions, 
including regional centres of 
excellence, in developing 
countries 
Governments; other international 
intergovernmental organizations; other 
relevant stakeholders (including 
research and development groups, 
relevant health-related industries and 
development partners)
X X X X
1. SDC: Support to TDR, contribution to national health systems, priorization of health care agenda in 
several countries; SECO
2. Swiss TPH has a strong engagement in Ifakara (TTCIH), Tanzania; SNSF
3. mediCuba-Suisse (national cancer clinic); Novartis Foundation support of TTCIH in Tanzania; SRC in 
Ghana
5. DNDi and NITD collaborate with different research institutions in the South; MMV mainly works with 
universitites in South Africa
3.1 c (c) strengthen health 
surveillance and information 
systems 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including 
nongovernmental organizations, 
research institutions, academia)
X X X X
1. SDC; SECO
2. Swiss TPH: large experience in Demographic Surveillance Systems
3. NGOs running in-country programs with data collection such as MFS, SolidarMed
4. Roche collaboration with google.org
3.2 a (a) establish and strengthen 
regulatory capacity in 
developing countries 
Governments; WHO; other relevant 
stakeholders (including national and 
regional regulatory agencies) X X X
1. SECO: Financing of capacity strengthening projects, financing of an investment and capacity building 
project in Azerbaijan; SDC; Swissmedic
2. New development within Swiss TPH
5. DNDi: Conduction of a regulatory workshop in Nairobi in June 2009
3.2 b (b) strengthen human resources 
in research and development in 
developing countries through 
long-term national capacity 
building plans 
Governments; other international 
intergovernmental organizations; other 
relevant stakeholders (including 
development partners; international 
and national research institutions)
X X 1. SDC: Support to TDR; FOPH2. Swiss TPH: Project on medical education in Tajikistan; SNSF: more short term activities (3 years)
3.2 c (c) encourage international 
cooperation to develop effective 
policies for retention of health 
professionals including 
researchers in developing 
countries  
Governments; WHO; other 
international intergovernmental 
organizations (including International 
Organization for Migration and ILO); 
other relevant stakeholders 
X X
1. SDC: Support to TDR; FOPH: Thematic document on migration of health workers
2. Swiss TPH: Mandate from BAG to formulate recommendations on effective and efficient practices in 
Switzerland to counteract migration of staff working in the health sector; SNSF: in the framework of DC 
programmes, membership in International Foundation for Science in Stockholm 
(3.2) framing, developing and supporting effective policies that promote the development of capacities for 
health innovation 
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1. Swiss 
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2. Aca-
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3. NGOs 4. Private 
sector
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Contribution of Switzerland
3.2 d (d) urge Member States to 
establish mechanisms to 
mitigate the adverse impact of 
the loss of health personnel in 
developing countries, 
particularly researchers, 
through migration, including by 
ways for both receiving and 
originating countries to support 
the strengthening of national 
health and research systems, in 
particular human resource 
development in the countries of 
origin, taking into account the 
work of WHO and other relevant 
organizations 
Governments
X 1. FOPH: Thematic document on migration of health workers; SDC
3.3 a (a) develop successful health 
innovation models in developing 
innovative capacity 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO, OECD 
and UNCTAD); other relevant 
stakeholders (including academia; 
research institutions; health related 
industries and developmental partners)
X X 1. SDC2. ZHUAS: Cooperation project with Health Sciences University of Mongolia
3.3 b (b) intensify North–South and 
South–South partnerships and 
networks to support capacity 
building 
Governments; WHO; other 
International intergovernmental 
organizations; other relevant 
stakeholders (including academia, 
research institutions, relevant health-
related industries)
X X X X X
1. SER: Support to the Swiss TPH; SECO: Financing of capacity strengthening projects, realisation of the 
'Swiss Vietnamese Intellectual Property Project'; SDC
2. Swiss TPH; ZHUAS: Cooperation project with Health Sciences University of Mongolia; University of Basel: 
Competence centre "Africa"; University of Zurich: building up partnerships with the Makerere University in 
Uganda and the National University of Rwanda; SNSF; RPDC; SCOPES; KFPE; HUG
3. North-South and South-South partnerships are part of many programmes of NGOs
4. Novartis through NVGH
5. Most activities done through such partnerships
3.3 c (c) establish and strengthen 
mechanisms for ethical review 
in the research and
Governments; WHO; other relevant 
stakeholders (including academia and 
research institutions) 1. SER: Participation in EDCTP; FOPH: Draft Gederal Law on human research; SDC
(3.3) providing support for improving innovative capacity in accordance with the needs of developing countries   
    
development process, including 
clinical trials, especially in 
developing countries 
 
X X X X 2. Conducted research follows international accepted ethical standards4. Conducted research follows international accepted ethical standards
5. Conducted research follows international accepted ethical standards
3.4 a (a) establish and strengthen 
national and regional policies to 
develop, support, promote 
traditional medicine 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including concerned 
communities)
X X 1. SDC3. medico international schweiz, BD
3.4 b (b) encourage and promote 
policies on innovation in the field 
of traditional medicine  
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including international 
and national research institutions, 
concerned communities)
X 1. SDC
3.4 c (c) promote standard setting to 
ensure the quality, safety and 
efficacy of traditional medicine, 
including by funding the 
research necessary to establish 
such standards 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including national and 
regional regulatory agencies; 
international and national research 
institutions; development partners; 
concerned communities)
X X X
1. SDC, Swissmedic
2. SNSF
3. Swiss Red Cross in Paraguay, mediCuba-Suisse
3.4 d (d) encourage research on 
mechanisms for action and 
pharmacokinetics of traditional 
medicine 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including academia; 
international and national research 
institution; relevant health-related 
industries; concerned communities)
X X X
1. SER; FOPH
2. SNSF
3. Esperanza Medicines Foundation
3.4 e (e) promote South-South 
collaboration in traditional 
medicine 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including research 
institutions, regional bodies, academia)
X 1. SDC
3.4 f (f) formulate and disseminate 
guidelines on good 
manufacturing practices for 
traditional medicines and laying 
down evidence-based standards 
f lit d f t l ti
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including national and 
regional regulatory agencies, relevant 
h lth l t d i d t i )
X 1. SDC, FOPH, Swissmedic
(3.4) supporting policies that will promote innovation based on traditional medicine within an evidence-based 
framework in accordance with national priorities and taking into account the relevant provisions of relevant 
international instruments 
or qua y an  sa e y eva ua on ea -re a e  n us r es
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Contribution of Switzerland
3.5 a (a) encourage the 
establishment of award 
schemes for health-related 
innovation 
Governments; [WHO]/[WHO]/[WHO]; 
other international intergovernmental 
organizations [(including WIPO)]; other 
relevant stakeholders (including 
academia; international and national 
research institution; development 
partners; charitable foundations)
X X 1. SER; SDC, SECO2. ZHUAS 
3.5 b (b) encourage recognition of 
innovation for purposes of 
career advancement for health 
researchers 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including academia; 
international and national research 
institution; development partners; 
charitable foundations)
X X X
1. SDC: Support to TDR; SER; SECO
2. Joint publications
5. Joint publications
4
4.1 a (4.1) promoting transfer of technology and the production of health products in developing countries (a) explore possible new 
mechanisms and make better 
use of existing mechanisms to 
facilitate transfer of technology 
and technical support to build 
and improve innovative capacity 
for health-related research and 
development, particularly in 
developing countries 
Governments; WHO; other 
international intergovernmental 
organizations (including WTO, 
UNCTAD, UNIDO, WIPO); other 
relevant stakeholders (including; 
international and national research 
institution;  relevant health-related 
industries)
X X X X
1. SECO: targeted aid at health infrastructure in Egypt
2. Swiss TPH: Through collaboration with local organisations; University of Geneva with RAFT 
3. NFSD with eLearning programmes such as ICATT and eLearning project in Ghana
5. DNDI and NITD: through collaboration with local organisations; MMV works mainly in the field of clinical 
trials with universities in the disease endemic countries.
4.1 b (b) promote transfer of 
technology and production of 
health products in developing 
countries through investment 
and capacity building  
Governments; WHO; other 
intergovernmental organizations; other 
relevant stakeholders (including health-
related industries) X X X X X
1. SER: Support to the Swiss TPH; SECO: Investment and capacity building projects, targeted aid at health 
infrastructure in Jordania and Egypt, financing of an investment and capacity building project in Ghana
2. Swiss TPH; SNSF
3. mediCuba-Suisse (transfer of raw material)
4. Roche Technology Transfer Initiative
5. DNDi has the strongest focus on technology transfer
4.1 c (c) promote transfer of 
technology and production of 
h lth d t i d l i
Governments; WHO; other 
international intergovernmental 
i ti th l t 1 SDC: Support to TDR and ANDI; SECO: Investment and capacity building projects targeted aid at health
Element 4. Transfer of technology
(3.5) developing and implementing, where appropriate, possible incentive schemes for health-related 
innovation 
ea  pro uc s n eve op ng 
countries through identification 
of best practices, and 
investment and capacity building 
provided by developed and 
developing countries where 
appropriate 
organ za ons;o er re evan  
stakeholders (including relevant health- 
related industries; academia; 
nongovernmental organizations; 
development partners; charitable 
foundations)  
X X X X X
.            ,     
infrastructure in Egypt, financing of an investment and capacity building project in Serbia
2. Swiss TPH
3. Novartis Foundation (support of the TTCIH); Swiss Aids Care International (transfer of know how and 
capacity building); most NGOs do capacity building in their programs
4. Roche Technology Transfer Initiative
5. DNDi has the strongest focus on technology transfer
4.2 a (4.2) supporting improved collaboration and coordination of technology transfer for health products, bearing in 
mind different levels of development 
(a) encourage North–South and 
South–South cooperation for 
technology transfers, and 
collaboration between 
institutions in developing 
countries and the 
pharmaceutical industry 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO); other 
relevant stakeholders (including 
relevant health-related industries; 
international and national research 
institutions; academia; 
nongovernmental organizations; 
development partners)
X X X X X
1. SER: Bilateral research program with South Africa; SDC: Support to research institutions
2. Swiss TPH: ARCEAU project
3. Afro-European Medical and Research Network
4. Roche Technology Transfer Initiative
5. MMV, DNDi and NITD: through their collaborations with the pharmaceutical industry and local 
organisations
4.2 b (b) facilitate local and regional 
networks for collaboration on 
research and development and 
transfer of technology 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including relevant health-
related industries, national research 
institutions, academia; 
nongovernmental organizations) 
X X X
1. SDC: Support to TDR, ANDI, and COHRED
2. Swiss TPH:Member of the EANETT (Eastern African Network for Trypanosomiasis), ARCEAU project, 
SNSF: potential effect of joint research projects in the DC and SCOPES programme
5. DNDi: Involved in three regional networks for research capacity strengthening
4.2 c (c) continue to promote and 
encourage technology transfer 
to least-developed country 
members of the WTO 
consistent with Article 66.2 of 
the Agreement on Trade-
Related Aspects of Intellectual 
Property Rights 
Governments
X 1. IPI and SECO
4.2 d (d) promote the necessary 
training to increase absorptive 
capacity for technology transfer 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including research 
institutions)
X X X
1. SECO: targeted aid at health infrastructure in Egypt
2. Swiss TPH: Egypt - Swiss radiology project, sponsored by the Egyptian and Swiss governments; SNSF: 
potential effect of joint research projects in the DC and SCOPES programmes
3. SRC in Egypt, Eritrea, Zimbabwe: strengthening national blood transusion services
4.3 a (a) examine the feasibility of 
voluntary patent pools of 
upstream and downstream 
technologies to promote 
innovation of and access to 
health products and medical 
devices 
Governments; WHO; other international 
intergovernmental organizations 
(including WIPO); other relevant 
stakeholders (including international 
and national research institution;  
relevant health-related industries, 
nongovernmental organizations; 
d i )
X X 1. SECO and IPI3. Strong support for the UNITAID patent pool by MSF
(4.3) developing possible new mechanisms to promote transfer of and access to key health-related 
technologies 
aca em a
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Contribution of Switzerland
4.3 b (b) explore and, if feasible, 
develop possible  new 
mechanisms to promote 
transfer of and access to key 
health-related technologies of 
relevance to public health 
needs of developing countries 
especially on Type II and III 
diseases and the specific R&D 
needs of developing countries in 
respect of Type I diseases, 
which are consistent with the 
provisions of the TRIPS 
agreement and instruments 
related to that agreement, which 
provide flexibilities to take 
measures to protect public 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO, WTO); 
other relevant stakeholders (including 
health- related industries)
X X X
1. SECO and IPI
2. Swiss TPH: following the Global Access Strategy
5. DNDi, MMV, and NITD: following the Global Access Strategy
5
5.1 a (a) encourage and support the 
application and management of 
intellectual property in a manner 
that maximizes health-related 
innovation and promotes access 
to health products and that is 
consistent with the provisions in 
the TRIPS agreement and other 
WTO instruments related to that 
agreement and meets the 
specific R&D needs of 
developing countries
[Governments; WHO; other 
international intergovernmental 
organizations (including WIPO, WTO, 
UNCTAD); other relevant stakeholders 
(including international and national 
research institutions and development 
partners)])
X X X X
1. IPI: Carrying out of cooperation projects, start of a new project with Ghana and a new one with Serbia
2. Swiss TPH: following the Global Access Strategy
3. MSF
5. DNDi, MMV, and NITD: following the Global Access Strategy
5.1 b (b) promote and support, 
including through international 
cooperation, national and 
regional institutions in their 
efforts to build and strengthen 
capacity to manage and apply 
Governments; WHO/[WHO]; other 
international intergovernmental 
organizations (including 
[WIPO]/[WIPO], [WTO]/[WTO], 
UNCTAD; other relevant stakeholders 
(including international and national X X X
1. IPI: Carrying out of cooperation projects, offering free patent searches, start of a new project with Ghana
2. Swiss TPH: ARCEAU project; ZHUAS: Cooperation project with Health Sciences University of Mongolia 
5 DNDi t f it t f
Element 5. Application and Management of intellectual property to contribute to innovation and promote public health 
(5.1) support information sharing and capacity building in the application and management of intellectual 
property with respect to health related innovation and the promotion of public health in developing countries 
intellectual property in a manner 
oriented to public health needs 
and priorities of developing 
countries 
research institutions and development 
partners)
. : s rong ocus on capac y rans er
5.1 c (c) Facilitate widespread access 
to, and promote further 
development of, including, if 
necessary, compiling, 
maintaining and updating, user-
friendly global databases which 
contain public information on 
the administrative status of 
health-related patents, including 
supporting the existing efforts 
for determining the patent status 
of health products, in order to 
strengthen national capacities 
for analysis of the information 
contained in those databases, 
and improve the quality of 
patents. 
[Governments]/[Governments]; 
[WHO]/[WHO]; other international 
intergovernmental organizations 
(including [WIPO]/[WIPO], 
[WTO]/[WTO], [UNCTAD]; other 
relevant stakeholders (including 
international and national research 
institutions and development partners)]
X 1. IGE
5.1 d (d) stimulate collaboration 
among pertinent national 
institutions and relevant 
government departments, as 
well as between national, 
regional and international 
institutions, in order to promote 
information sharing relevant to 
public health needs 
Governments; WHO; Other 
international intergovernmental 
organizations; Other relevant 
stakeholders (including academia; 
international and national research 
institutions; development agencies; 
nongovernmental organizations; 
relevant health-related industries) 
X X X
1. IPI: Interministerial expert group on health and intellectual property; FOPH: interministerial expert group 
on health and intellectual property; SECO
2. Swiss TPH support in Tanzania, leading house scientific collaboration with South Africa, Centre Suisse de 
la Recherche Scientifique en Côte d'Ivoire, ARCEAU project in DRC
5. NITD in Singapore and Indonesia; DNDI in Malaysia, India, Brazil and Kenya
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Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
5.1 e (e) strengthen education and 
training in the application and 
management of intellectual 
property, from a public health 
perspective taking into account 
the provisions contained in the 
Agreement on Trade-Related 
Aspects of Intellectual Property 
Rights, including the flexibilities 
recognized by the Doha 
Ministerial Declaration on the 
TRIPS Agreement and Public 
Health and other WTO 
instruments related to the 
TRIPS agreement 
Governments; [WHO]/[WHO]; other 
international intergovernmental 
organizations (including 
[WIPO]/[WIPO], [WTO]/[WTO], 
[UNCTAD]/[UNCTAD]); other relevant 
stakeholders (including international 
and national research institutions and 
development partners)
X X 1. IPI: support of WTO and WIPO seminars3. BD; different campaigns supported by a number of NGOs
5.1 f (f) facilitate, where feasible and 
appropriate, possible access to 
traditional medicinal knowledge 
information for use as prior art in 
examination of patents, 
including, where appropriate, 
the inclusion of traditional 
medicinal knowledge 
information in digital libraries 
Governments; [WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including] concerned 
communities)
X 1. IPI
5.1 g (g) promote active and effective 
participation of health 
representatives in intellectual 
property-related negotiations, 
where appropriate, in order that 
such negotiations also reflect 
public health needs 
Governments;
X 1. IPI and FOPH
5.1 h (h) strengthen efforts to 
effectively coordinate work  
relating to intellectual property
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO WTO     
and public health among the 
Secretariats and governing 
bodies of relevant regional and 
international organizations to 
facilitate dialogue and 
dissemination of information to 
countries   
  , , 
and UNCTAD)
X 1. IPI and FOPH
5.2 a (a) consider, whenever 
necessary, adapting national 
legislation in order to use to the 
full the flexibilities contained in 
the Agreement on Trade-
Related Aspects of Intellectual 
Property Rights, including those 
recognized by the Doha 
Declaration on TRIPS 
Agreement and Public Health 
and the WTO decision of 30 
August 2003 
Governments; WHO; Other 
international intergovernmental 
organizations (including WIPO, WTO 
and UNCTAD)
X 1. IPI
5.2 b (b)Take into account, where 
appropriate, the impact on 
public health when considering 
adopting or implementing more 
extensive intellectual property 
protection than is required by 
the Agreement on Trade-
Related Aspects of Intellectual 
Property Rights, without 
prejudice to the sovereign rights 
of Member States
Governments; [WHO; Other 
international intergovernmental 
organizations (including WIPO, WTO 
and UNCTAD)]
X X X
1. IPI
2. Swiss TPH: following the Global Access Strategy
5. DNDI, MMV and NITD: following the Global Access Strategy
5.2 c (c) take into account in trade 
agreements the flexibilities 
contained in the Agreement on 
Trade-Related Aspects of 
Intellectual Property Rights and 
including those recognized by 
the Declaration on the TRIPS 
Agreement and Public Health 
adopted by the WTO Ministerial 
Conference (Doha, 2001) and 
the WTO decision of 30 August
Governments
X 1. IPI and SECO
(5.2) providing as appropriate, upon request, in collaboration with other competent international organizations 
technical support, including, where appropriate, to policy processes, to countries that intend to make use of the 
provisions contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights, including the 
flexibilities recognized by the Doha Ministerial Declaration on the TRIPS Agreement and Public Health and 
other WTO instruments related to the TRIPS agreement, in order to promote access to pharmaceutical 
products 
      
2003 
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Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
5.2 d (d) consider, where appropriate, 
taking necessary measures in 
countries with manufacturing 
capacity to, facilitate through 
export, access to 
pharmaceutical products in 
countries with insufficient or no 
manufacturing capacity in the 
pharmaceutical sector in a 
manner consistent with the 
Agreement on Trade-Related 
Aspects of Intellectual Property 
Rights, the Doha Declaration on 
the TRIPS Agreement and 
Public Health and the WTO 
decision of 30 August 2003 
Governments 
X 1. IPI: Implementation of WTO General Council decision of August 30, 2003.
5.2 e (e) encourage finding ways, in 
ongoing discussions, to prevent 
misappropriation of health-
related traditional knowledge, 
and consider where appropriate 
legislative and other measures 
to help prevent misappropriation 
of such traditional knowledge 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO, WTO, 
UNEP/Secretariat of the Convention on 
Biological Diversity); other relevant 
stakeholders (including concerned 
communities)
X X 1. IPI: obligation of declaration for the source of genetic resources and traditional knowledge3. medico international schweiz, BD
5.3 a (5.3) exploring and, where appropriate, promoting  possible incentive schemes for research and development 
on Type II and Type III diseases and on developing countries’ specific research and development needs in 
relation to Type I diseases 
(a) explore and, where 
appropriate, promote a range of 
incentive schemes for research 
and development including 
addressing, where appropriate, 
the de-linkage of the costs of 
research and development and 
the price of health products, for 
example through the award of 
prizes, with the objective of 
addressing diseases which
[Governments; [WHO]/[WHO]; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including international 
and national research institutions; 
development partners; charitable 
foundations; relevant health related 
industries; nongovernmental 
organizations)]
X 1. SDC; SECO; IPI; FOPH
   
disproportionately affect 
developing countries  
6
6.1 a (a) invest in developing health-
delivery infrastructure and 
encourage financing of health 
products 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including development 
partners,  charitable foundations, 
private sector and relevant health-
related industries) 
X X X X X
1. SDC: Support to national health programmes; FOPH: Premium for innovation 
2. Swiss TPH is partner in different access programs
3. several NGOs
4. Access programmes of Novartis and Roche
5. DNDi focus on advocacy for access but is not directly involved in access programs, MMV has access 
programs
6.1 b (b) develop effective and 
sustainable mechanisms in 
least-developed countries in 
order to improve access to 
existing medicines, 
acknowledging the transitional 
period until 2016[1] 
Governments; WHO; other 
international intergovernmental 
organizations (including WTO); other 
relevant stakeholders
X X X X X
1. SDC: support to priortize health care in national agendas; IPI; SECO
2. Swiss TPH is partner in different access programs; ZHUAS: Cooperation project with Health Sciences 
University of Mongolia
3. Novartis Foundation access programmes
4. Access programmes of Novartis and Roche
5. DNDi focus on advocacy for access but is not directly involved in access programs, MMV has access 
programs
6.1 c (c) prioritize health care in 
national agendas 
Governments X 1. SDC; FOPH
6.1 d (d) encourage health authorities 
to improve domestic 
management capacities in order 
to improve delivery and access 
to medicines and other health 
products with quality, efficacy, 
safety and affordability and, 
where appropriate, to develop 
strategies to promote rational 
use of medicines 
Governments; WHO
X 1. SDC: Contributions to TDR; FOPH
Element 6. Improving delivery and access 
(6.1) encouraging increased investment in the health-delivery infrastructure and financing of health products in 
order to strengthen the health system 
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Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
6.1 e (e) increase investment in 
human resource development 
in the health sector 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including development 
partners; nongovernmental 
organizations; charitable foundations)  
X X X X X
1. SDC: SWAp and Health sector budget support
2. Investment through capacity building/training
3. Investment through capacity building/training, through creating work opportunities in developing countries
4. Roche skills transfer and capacity building programmes, NVGH strong focus on capacity building
5. Investment through capacity building/training, through creating work opportunities in developing countries
6.1 f (f) develop effective country 
poverty reduction strategies that 
contain clear health objectives 
Governments; other relevant 
stakeholders (including development 
partners) X X
1. SDC
2. Swiss TPH contributes through development programmes, for example health systems strengthening in 
Tanzania
6.1 g (g) encourage pooled 
procurement mechanisms for 
health products and medical 
devices, where appropriate 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders
X X 1. IPI5. MMV: close alignment with AMFm initiative
6.2 a (6.2) establishing and strengthening mechanisms to improve ethical review and regulate the quality, safety and 
efficacy of health products and medical devices 
(a) develop and/or strengthen 
the capacity of national 
regulatory authorities to monitor 
the quality, safety and efficacy 
of health products while 
sustaining ethical review 
standards 
Governments; WHO; other relevant 
stakeholders (including national and 
regional regulatory agencies and 
development partners)
X X X
1. FOPH, Swissmedic
2. Swiss TPH involvment in AMASA FP7 project
5. DNDi: regulatory workshop in Nairobi in June 2009
6.2 b (b) promote operational 
research to maximize the 
appropriate use of new and 
existing products, including cost-
effective and affordable 
products in high disease-burden 
settings 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including international 
and national research institutions; 
nongovernmental organizations, 
development partners and charitable 
foundations)
X X X X
1. SDC; FOPH
2. Swiss TPH actively involved in different access programs; ZHUAS: Cooperation project with Health 
Sciences University of Mongolia
3. Several NGOs such as SolidarMed, Novartis Foundation, Swiss Red Cross, MSF, etc.
5. MMV: Access programs
6.2 c (c) comply with good 
manufacturing practices for 
safety standards, efficacy and 
lit f h lth d t
Governments;  WHO; other relevant 
stakeholders (including national 
regulatory bodies; relevant health-
l t d i d t i d l t
X X X
1. SDC; FOPH; Swissmedic
4. Novartis and Roche
5 DNDi MMV th h th f l l ti f th i i t t f th d ti f th di iqua y o  ea  pro uc s re a e  n us r es; eve opmen  
partners
. , : roug  e care u  se ec on o  e r pr va e par ners or e pro uc on o  e me c nes
6.2 d (d) strengthen the WHO pre-
qualification programme 
Governments; WHO, other international 
intergovernmental organizations; other 
relevant stakeholders (including 
development partners)  
X X 1. FOPH; Swissmedic5. WHO prequalification of product developed by DNDi and MMV 
6.2 f (f) where appropriate, initiate 
programmed actions on 
regional and sub-regional levels 
with the ultimate goal of 
harmonization of processes 
employed by the regulatory 
authorities for drug marketing 
approvals 
Governments; [WHO]/[WHO]; other 
relevant stakeholders (including 
national and regional regulatory 
agencies, regional bodies and 
development partners) X X
1. Swissmedic
5. DNDi: regulatory workshop in Nairobi in June 2009
6.2 g (g) promote ethical principles for 
clinical trials involving human 
beings as a requirement of 
registration of medicines and 
health-related technologies, with 
reference to the Declaration of 
Helsinki, and other appropriate 
texts, on ethical principles for 
medical research involving 
human subjects, including good 
clinical practice guidelines  
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including national and 
regional regulatory agencies)
X X X X
1. SER: Participation in EDCTP; FOPH Draft Federal Law on human research; SDC; IPI
2. Swiss TPH: clinical trials are conducted according to international approved standards; 
4. Clincal trials are conducted according to international approved standards
5. Clinical trials are conducted according to international approved standards; NITD only conducts proof-of-
concept clinical trials
6.2 h (h) support regional networks 
and collaborative efforts to 
strengthen the regulation and 
implementation of clinical trials 
using appropriate standards for 
medicines evaluation and 
approval 
Governments; WHO; other relevant 
stakeholders (including national and 
regional regulatory agencies, 
international and national research 
institutions, regional bodies and 
development partners)
X X X X
1. SER: Participation in EDCTP; SDC; FOPH; Swissmedic
2. Swiss TPH: Clinical trials are conducted according to international approved standards; the clinical trials 
are conducted in collaboration with local partners; 
4. Roche: internship programme at the clinical pharmacology unit
5. Clinical trials are conducted according to international approved standards; the clinical trials are 
conducted in collaboration with local partners
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Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
6.3 a (a) support the production and 
introduction of generic versions, 
in particular of essential 
medicines, in developing 
countries, through the 
development of national 
legislation and/or policies that 
encourage generic production 
and entry, including a 
“regulatory exception” or “Bolar”-
type provision, and which are 
consistent with the Agreement 
on Trade-Related Aspects of 
Intellectual Property Rights and 
instruments related to that 
agreement 
Governments
X 1. IPI: Implementation of a bolar-type provision; SDC; SECO; FOPH
6.3 b (b) frame and implement 
policies to improve access to 
safe and effective health 
products, especially essential 
medicines, at affordable prices, 
consistent with international 
agreements 
Governments; WHO; other 
international intergovernmental 
organizations (including WTO and 
WIPO); other relevant stakeholders
X X X X
1. FOPH
2. Geneva Health Forum
3. MSF
5. MMV: close alignment to AMFm initiative
6.3 c (c) consider where appropriate, 
inter alia, the reduction or 
elimination of import tariffs on 
health products and medical 
devices and the monitoring of 
supply and distribution chains 
and procurement practices to 
minimize cost and increase 
access 
Governments
X 1. SECO
6.3 d (d) encourage pharmaceutical 
companies and other health
Governments; WHO;  
other international intergovernmental
(6.3) promoting competition to improve availability and affordability of health products consistent with public 
health policies and needs 
   -
related industries to consider 
policies, including differential 
pricing policies, that are 
conducive to promoting access 
to quality, safe, efficacious and 
affordable health products in 
developing countries, consistent 
with national law 
   
organizations; other relevant 
stakeholders (including relevant health-
related industries)
X X X X
1. SECO; FOPH
2. Swiss TPH: following the Global Access Policy
3. MSF
5. DNDi, MMV and NITD: following the Global Access Policy
6.3 e (e) consider, where appropriate, 
the development of policies to 
monitor pricing and to improve 
affordability of health products; 
further support WHO’s ongoing 
work on pharmaceutical pricing
Governments
X 1. FOPH
6.3 f (f) Consider, where necessary, 
and provided that they are 
consistent with the provisions of 
the Agreement on TRIPS, 
taking appropriate measures to 
prevent the abuse of intellectual 
property rights by right holders 
or the resort to practices which 
unreasonably restrain trade or 
adversely affect the international 
transfer of technology, in the 
field of health products
Governments
X 1. IPI; SECO
6.3 g (g) increase information among 
policy makers, users, doctors 
and pharmacists regarding 
generic products 
Governments; WHO other relevant 
stakeholders (including 
nongovernmental organizations and 
relevant health related industry)
X X 1. FOPH2. Swiss TPH: strong involvement in the health sector in Tanzania
7 Element 7. Promoting sustainable financing mechanisms 
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Number Elements and sub-elements Specific actions Stakeholder(s)*
1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
7.1 a (7.1) endeavoring to secure adequate and sustainable financing for research and development, and improve 
coordination of its use, where feasible and appropriate, in order to address the health needs of developing 
countries 
(a) establish a results-oriented 
and time-limited expert working 
group under the auspices of 
WHO and linking up with other 
relevant groups to examine 
current financing and 
coordination of research and 
development, as well as 
proposals for new and 
innovative sources of financing 
to stimulate R&D related to 
Type II and Type III diseases 
and the specific R&D needs of 
developing countries in relation 
to Type I diseases 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders
X 1. SER; SDC
7.1 b (b) consider channelling 
additional funds to health-
oriented research organizations 
as appropriate in both the 
private and public sector of 
developing countries and 
promote good financial 
management to maximize its 
effectiveness as recommended 
by the resolution WHA58.34 
Governments; WHO; other 
international intergovernmental 
organizations; other relevant 
stakeholders (including development 
partners,  charitable foundations, 
international and national research 
institutions, academia, private sector 
and relevant health-related industries)
X
1. SER; SDC
7.1 c (c) create a database of 
possible sources of financing for 
R & D 
Governments; WHO; other relevant 
stakeholders X X 1. SER; SDC2. SNSF
7.2 a  (7.2) facilitating the maximum use of, and complementing as appropriate, existing financing, including that 
through public-private and product development partnerships, in order to develop and deliver safe, effective 
and affordable health products and medical device
(a) document and disseminate 
best practices in public-private 
and product development 
partnerships 
Governments;  WHO; other relevant 
stakeholders (including research 
institutions, public-private and product 
development partnerships)
X X X X X
1. SER; SDC; SECO
2, 3 and 4. As partners in PPPs and PDPs: annual/biannual reports
5. Information sharing through the open publication of annual/biannual reports
7.2 b (b) develop tools to periodically 
assess performance of public-
i t d d t
Governments;  WHO; other relevant 
stakeholders (including research 
i tit ti bli i t d d tpr va e an  pro uc  
development partnerships 
ns u ons; pu c-pr va e an  pro uc  
development partnerships; charitable 
foundations) 
X 1. SDC; SECO
7.2 c (c) support public-private and 
product development 
partnerships and other 
appropriate research and 
development initiatives in 
developing countries 
Governments; WHO; other international 
intergovernmental organizations; other 
relevant stakeholders (including 
relevant health-related industries, 
charitable foundations, development 
partners, nongovernmental 
organizations; academia; research 
institutions)
X X X X X
1. SER; SDC
2. Swiss TPH: many activities are conducted in PPP/PDPs; SNSF
3. NFSD
4. Roche and Novartis
5. DNDi; MMV; NITD
8
8.1 a (8.1) measuring performance and progress towards objectives contained in the strategy and plan of action (a) establish systems to monitor 
performance and progress of 
the implementation of each 
element of the global strategy 
and plan of action 
Governments; WHO
X 1. FOPH: Secondment of an IP expert at WHO; SER; SDC; SECO; IPI; Swissmedic
8.1 b (b) monitor and report 
periodically to WHO’s governing 
bodies on the gaps and needs 
related to health products and 
medical devices in developed 
and developing countries 
Governments;  WHO
X 1. FOPH: Secondment of an IP expert at WHO; SDC
8.1 c (c) to continue to monitor, from 
a public health perspective, in 
consultation as appropriate with 
other international 
organizations, the impact of 
intellectual property rights and 
other issues addressed in the 
report of the Commission on 
Intellectual Property Rights, 
Innovation and Public Health, on 
the development of, and access 
to, health care products, and to 
report thereon to the Health 
Assembly 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO and 
WTO); other relevant stakeholders
X 1. FOPH: Secondment of an IP expert at WHO; IPI
Element 8. Establishing monitoring and reporting systems
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1. Swiss 
Federal 
Offices
2. Aca-
demic 
sector
3. NGOs 4. Private 
sector
5. PPPs Activities (key word + n° - see separate list by office)
Contribution of Switzerland
8.1 d (d) monitor and report on the 
impact of incentive mechanisms 
on innovation of and access to 
health products and medical 
devices 
Governments; WHO; other 
international intergovernmental 
organizations (including WIPO and 
WTO); Other relevant stakeholders X 1. FOPH: Secondment of an IP expert at WHO; SECO
8.1 e (e) monitor and report on 
investment in research and 
development to address the 
health needs of developing 
countries 
Governments; WHO; other relevant 
stakeholders
X 1. SER; SDC
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